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Abstract 
A growing number of studies have investigated novel roles of the alpha1-adrenoceptor 
(1-AR;  a receptor for sympathetic neurotransmitter catecholamines) in inflammation. 
Stimulation of 1-AR in immune cells modulates cellular functions, including migration 
and inflammatory cytokine production. However, whether 1-ARs in the skin play a 
role in cutaneous inflammation is not well understood. Complex regional pain 
syndrome (CRPS) is a complex and debilitating type of neuropathic pain. In the acute 
stage of CRPS, excessive inflammation persists in the affected limb. Moreover, 1-
AR expression is heightened in the skin of the affected limb. However, the causes of 
this upregulation of cutaneous 1-AR expression and whether this upregulation 
contributes to the persistent inflammation are unknown.  
In this study, the role of 1-AR in cutaneous inflammation was explored, in both 
normal and pathological conditions, utilizing in vitro, in vivo and ex vivo approaches. 
It was hypothesized that inflammatory mediators produced by keratinocytes, as a 
response to injury, would up-regulate 1-AR expression in these cells, and that 
heightened expression of 1-AR would increase 1-AR sensitivity to stimulation, 
leading to further release of inflammatory mediators from keratinocytes. Moreover, in 
CRPS, it was hypothesized that this feedback loop would be amplified and the 
response stronger than in healthy controls.  
A positive feedback interaction between 1-AR and inflammatory mediators in 
keratinocytes was demonstrated. In particular, 1-AR expression increased after 
exposure to the primary proinflammatory cytokine tumour necrosis factor  (TNF). 
Furthermore, activation of 1-AR further induced a pro-inflammatory cytokine, 
interleukin 6 (IL-6), expression, thereby suggesting a positive feedback loop between 
1-AR and IL-6 in keratinocytes. Interestingly, the interaction was stronger in 
keratinocytes obtained from CRPS patients, particularly those with high baseline 
levels of 1-AR expression, compared to healthy controls.  
In conclusion, this study demonstrated a positive feedback interaction between 1-
AR and IL-6 in the skin, which may play an important role in normal cutaneous 
inflammation. Maintaining homeostasis of this interaction could be crucial to prevent 
the development of persistent inflammation underlying pathophysiology in chronic 
diseases, such as CRPS.   
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Chapter 1. Introduction 
1.1. General Overview 
A role of alpha1-adrenoceptors (1-AR) in mediating cross-talk between the 
sympathetic nervous system and the immune system has been suggested. This 
highlights a possible role of 1-AR in inflammation. In immune cells, key players in 
inflammation, a positive feedback interaction between the 1-AR and inflammatory 
mediators has been demonstrated and may play an important role in normal 
inflammation. However, exaggeration and dysfunction of this interaction may 
contribute to the development of chronic inflammatory diseases.  
The acute stage of complex regional pain syndrome (CRPS) is associated with 
excessive cutaneous inflammation, marked by increased inflammatory mediator 
levels and heightened 1-AR expression in the skin (Huygen et al., 2002; Huygen et 
al., 2004a; Birklein et al., 2014; Drummond et al., 2014a; Drummond et al., 2014c; 
Finch et al., 2014). However, there are knowledge gaps in the role of 1-AR in 
cutaneous inflammation; specifically, what causes an increase in cutaneous 1-AR 
expression, what are the consequences of this upregulation, and whether 1-AR 
interact with inflammatory mediators in the skin. In this study, I will investigate these 
research questions to provide better insight into the interaction between 1-AR and 
inflammatory processes in the skin. This knowledge is important and may provide a 
potential therapeutic target to prevent the development of persistent inflammation in 
pathological conditions. 
The first part of this chapter outlines fundamental literatures on the sympathetic 
nervous system, the 1-AR and inflammation. The second part describes evidence 
on 1-AR-mediated cross-talk between the sympathetic nervous system and the 
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immune system and how this cross-talk may contribute to the development of certain 
pathological conditions such as chronic inflammatory diseases and cancer. The last 
part identifies knowledge gaps in the role of 1-AR in cutaneous inflammation, and 
how this knowledge may be important in chronic pain conditions such as CRPS is 
discussed.  
 
1.2. The sympathetic nervous system and adrenoceptors 
The sympathetic nervous system (SNS) is part of the autonomic nervous system and 
plays a role in the fight-or-flight response, triggered by fear, threat and stress. The 
sympathetic chain is located next to the vertebral column with preganglionic 
sympathetic neurons arising from the thoracic (T1) to lumbar (L2) part of the spinal 
cord and each preganglionic neuron synapses with several postganglionic neurons 
(approximately 1:20 ratio) (McCorry, 2007). These postganglionic sympathetic 
neurons exit the chain and terminate on effector tissues such as heart (Coote & 
Chauhan, 2016), tracheobronchial blood vessels of the airways (Nadel & Barnes, 
1984; van der Velden & Hulsmann, 1999), eyes (McDougal & Gamlin, 2015), kidney 
(Burnstock & Loesch, 2015), and cutaneous blood vessels (Ruocco et al., 2002). 
Upon activation, the SNS releases neurotransmitter catecholamines, such as 
noradrenaline, from post-ganglionic neurons. These catecholamines bind to 
adrenoceptors (ARs) to modulate the physiological function of target tissues, such as 
heart rate and blood pressure regulation (Carrier & Bishop, 1972; Herman & Sandoval, 
1983; McCorry, 2007), bronchodilation (Nadel & Barnes, 1984), vasoconstriction 
(Alosachie, 1988), and pupil dilation (McDougal & Gamlin, 2015; Larsen & Waters, 
2018). In the skin, the sympathetic nerves innervate several target tissues, such as 
hair follicles, arrector pili muscles, sweat glands and cutaneous blood vessels, which 
are involved in thermoregulation (Donadio et al., 2006; Glatte et al., 2019). The 
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catecholamine noradrenaline released from the SNS regulates skin cell function, such 
as keratinocyte proliferation to promote hair growth (Kong et al., 2015) and fibroblast 
proliferation and migration during wound healing (Wallert et al., 2011; Liao et al., 
2014). 
The ARs are transmembrane proteins and members of G protein-coupled receptors 
(GPCRs). These receptors are divided into two types, i.e. - and -adrenoceptors, 
based on their response to catecholamine stimulation. The -ARs mediate excitatory 
functions of the tissues, while the -ARs mediate inhibitory functions, with some 
exceptions depending on the tissues (Ahlquist, 1948). Each type of AR is further 
classified into the following subtypes: 1A, 1B, 1D, 2A, 2B, 2C, 1, 2, and 3 (see 
review in (Civantos Calzada & Aleixandre de Artinano, 2001)). The summary of the 
AR classification is presented in Figure 1-1. 
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This study will focus on exploring the role of 1-AR under normal and pathological 
conditions. The main aims of this study are to investigate the role of 1-AR in 
regulating inflammation, and how alterations in this role may trigger the development 
of some inflammatory pathological conditions. 
  
1.3. Alpha1-adrenoceptors  
The 1-adrenoceptor (1-AR) is located post-synaptically and is mainly expressed in 
smooth muscles. As a member of GPCR subclass Gq/11, catecholamine binding to 1-
AR activates the Gq/11 signalling pathway which results in intracellular Ca2+ release 
from the endoplasmic reticulum. This Ca2+ efflux works together with diacyl-glycerol 
(DAG) to activate protein kinase C (PKC), which mediates activation of other cellular 
responses (Figure 1-2; (Bruce et al., 2014)). Classically, a normal physiological role 
of 1-AR is to modulate smooth muscle contraction, growth and proliferation, 
specifically in the cardiovascular system. The aorta, the biggest arterial vessel, has 
abundant smooth muscle cells in its tunica media layer. Incubation of rat aorta with 
the 1-AR specific agonist phenylephrine stimulates its contraction (Doggrell, 1992). 
Moreover, 1-AR stimulation in rat vascular smooth muscle cells induces DNA 
synthesis, cell growth and proliferation (Nakaki et al., 1990). As part of the 
cardiovascular system, the heart also expresses 1-AR, specifically on the cardiac 
myocytes (review on (O'Connell et al., 2014)). Signalling through 1-AR is 
cardioprotective. Normal physiological functions of 1-AR in the heart include 
providing a protection against cardiac cell death, inducing cardio protection and 
positive inotropy, facilitating normal adaptive hypertrophy without affecting the 
contractile functions of the cardiomyocytes (O'Connell et al., 2014).       
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Figure 1-2. The Gq/11 signalling pathway.  
An activation of GPCR through the binding of its ligands results in a dissociation of 
the GPCR -subunit from its complex (1). The -subunit activates phospholipase C 
(PLC) (2) to hydrolyse phosphatidylinositol 4,5-biphosphate (PIP2) into diacyl-glycerol 
(DAG) and inositol (1,4,5) triphosphate (IP3) (3). A binding of IP3 to calcium channels 
on the endoplasmic reticulum membrane (4) results in Ca2+ mobilization to cytoplasm 
(5). Furthermore, a phosphorylation of protein kinase C (PKC) by DAG (6) and Ca2+ 
efflux from the endoplasmic reticulum further activates other cellular responses 
((Bruce et al., 2014) with some modifications compiled by L. Wijaya). 
 
Based on growing molecular and pharmacological studies, the 1-AR is further 
classified into several subtypes, i.e. 1-AR subtype A (1A-AR), 1B-AR and 1D-AR 
(reviewed by (Piascik & Perez, 2001)). The expression levels and the function of each 
AR subtype vary depending on the cell or tissue in which they are expressed (Kikuchi-
Utsumi et al., 1997; Jensen et al., 2011; O'Connell et al., 2014). In addition, 1-AR 
stimulation results in differential regulation on each 1-AR subtype expression. As an 
example, in adult rat cardiomyocytes, stimulation of 1-AR leads to an increase in 
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1A-AR and a decrease in both 1B-AR and 1D-AR (Rokosh et al., 1996). Similar 
reduction in 1B-AR expression following 1-AR stimulation was also shown in 
neonatal rat cardiomyocytes (Luther et al., 2001).  
Growing evidence shows that other tissues/cells, such as brain, liver, kidney, spleen 
(Price et al., 1994), spinal cord (Giroux et al., 1999) and dorsal root ganglia (DRG; 
(Nicholson et al., 2005; Dawson et al., 2011)), glial cells (Kulik et al., 1999), bone cells 
(Obata et al., 2007; Suga et al., 2010), immune cells (Heijnen et al., 1996; Ricci et al., 
1999), and keratinocytes (Dawson et al., 2011; Li et al., 2013), also express 1-AR. 
This has prompted investigation of novel physiological roles of 1-AR. For example, 
in the brain, the expression of 1-AR has been found widely in neurons and glial cells 
(Kulik et al., 1999). While the role of 1-AR in the brain is not fully understood, some 
important roles of 1-AR in facilitating normal brain function, such as neurogenesis, 
gliogenesis, and behavioural responses to an environmental change have been 
suggested (Stone et al., 1999; Gupta et al., 2009). Specifically, impaired 1-AR 
signalling in the brain may be involved in depression, cognitive dysfunction and drug-
induced locomotor activity (Nalepa et al., 2013). In osteoclasts, bone cells that have 
a role in bone remodelling, signalling through 1-AR mediates nerve-bone cell 
interaction during osteoclastogenesis (development of osteoclasts; (Suga et al., 
2010)). Stimulation of 1-AR leads to osteoclastic cell activation and production of 
interleukin (IL)-6, a cytokine that supports proliferation and differentiation of 
osteoclast progenitors. Since the discovery of 1-AR expression in several types of 
immune cells, a growing number of studies have investigated the involvement of 1-
AR signalling in modulating immune cell functions (Ricci et al., 1999; Roupe van der 
Voort et al., 2000; Rouppe van der Voort et al., 2000; Kavelaars, 2002; Maestroni, 
2006; Grisanti et al., 2011a), which includes their migration and inflammatory cytokine 
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production (Heijnen et al., 1996; Maestroni, 2000; Roupe van der Voort et al., 2000; 
Grisanti et al., 2011b). This highlights a possible involvement of 1-AR in inflammation.  
 
1.4. Inflammation  
Inflammation is a complex and important physiological process to combat infection 
and initiate repair after injury. Following an injury, acute inflammatory responses from 
local tissues are activated. Key pro-inflammatory cytokines, such as tumour necrosis 
factor  (TNF), interleukin (IL)-1 and IL-6, and growth factors such as nerve growth 
factor (NGF), are released by immune cells and resident cells, such as keratinocytes 
in the skin, to promote an inflammatory response and initiate the healing process 
(Zhang & An, 2007; Bernard et al., 2012; Shi et al., 2013; Birklein et al., 2014).  
In acute inflammation, some clinical presentations such as redness, swelling, heat, 
loss of function and pain, are observed at the site of injury. These physiological signs 
of inflammation also reflect changes at cellular levels, such as (1) activation of 
inflammatory pathways by harmful environmental stimuli, (2) inflammatory cytokine 
and growth factor release by both resident immune cells, such as macrophages, and 
resident structural skin cells, such as keratinocytes and fibroblasts, (3) recruitment of 
circulating immune cells to the site of injury, (4) an increased permeability of vascular 
endothelium to allow selective extravasation of plasma protein and neutrophils from 
blood vessels to the injured site, and (5) resolution of inflammation and initiation of 
tissue repair and remodelling (Libby, 2007; Medzhitov, 2008; Takeuchi & Akira, 2010; 
Chen et al., 2017a).  
Inflammatory mediators activate nociceptors indirectly or directly by binding to their 
receptors on primary afferent nociceptors (Chao, 2003; Ji et al., 2014; Cook et al., 
2018). Thus, inflammatory mediators induce pain. As examples, an injection of a pro-
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inflammatory cytokine, such as TNF or IL-1, to uninjured animals induces 
neuropathic pain behaviours (hyperalgesia and allodynia), as intense as the pain that 
arises from peripheral nerve injury (Wagner & Myers, 1996a; Schafers et al., 2003; 
Zelenka et al., 2005). Moreover, this pain is aggravated when inflammatory mediators 
are administered locally to injured nerves (DeLeo et al., 1996; Schafers et al., 2003; 
Kim & Moalem-Taylor, 2011). On the contrary, administration of neutralizing agents 
to inflammatory mediators (Clatworthy et al., 1995; Schafers et al., 2001) or deletion 
of genes expressing these mediators, can alleviate the pain (Ramer et al., 1998; Kim 
& Moalem-Taylor, 2011). In normal inflammatory processes, this pain usually 
disappears once the healing process is completed. 
TNF is a pro-inflammatory cytokine and plays an important role in the innate immune 
system. In the skin, resident cells such as keratinocytes, fibroblasts and macrophages 
produce TNF locally, following tissue injury (Fahey et al., 1995; Zelova & Hosek, 
2013). TNF signals through its receptors, mainly TNF receptor type 1 (TNFR1) and 
TNFR2, to activate different cellular responses (Bradley, 2008). Signalling through 
TNFR1 mediates activation of inflammatory signalling cascades and programmed cell 
death pathways (Bradley, 2008), while TNFR2 promotes cell migration and 
proliferation (Bradley, 2008). TNF acts very rapidly. A study using cultured human 
keratinocytes showed that administration of TNF induced expression of genes 
involved in innate immunity and inflammation as early as 1 hour after exposure 
(Banno et al., 2004).  
Growing evidence has shown cross-talk between cytokines and growth factors, such 
as nerve growth factor (NGF), that contributes to the inflammatory process (Lindholm 
et al., 1987; Olgart & Frossard, 2001; Takei & Laskey, 2008b, 2008a). In vitro, the 
pro-inflammatory cytokines, IL-1 and TNF, induce NGF secretion from non-neuronal 
cells isolated from sciatic nerves (Lindholm et al., 1987), human pulmonary fibroblasts 
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(Olgart & Frossard, 2001), and neuronal cells (Takei & Laskey, 2008b). Reciprocally, 
NGF induces TNF expression in neuronal cells through the involvement of PKB/Akt 
(Protein Kinase B; an enzyme involved in the NGF signalling pathway) and NF-B 
(Nuclear Factor kappa-light-chain-enhancer of activated B cells; a transcription factor 
involved in inflammatory signalling pathways) activation (Takei & Laskey, 2008b). 
This positive feedback interaction between TNF and NGF is important for promoting 
neuronal cell survival; indeed, failure of this cross-talk may contribute to the 
pathophysiology of neurodegenerative diseases, such as Alzheimer’s disease (Takei 
& Laskey, 2008a).  
Excessive inflammatory responses are thought to contribute to the development of 
persistent inflammation and complicate the pathophysiology of some diseases, such 
as chronic inflammatory diseases (Bernard et al., 2012; Nedoszytko et al., 2014; Kim 
& Moudgil, 2017), chronic wound healing (Eming et al., 2007; Zhao et al., 2016), and 
chronic pain (Kramer et al., 2011; Marinus et al., 2011; Sommer et al., 2018). For 
example, arthritis is a chronic inflammatory autoimmune disease in which pro-
inflammatory cytokines, such as TNF, IL-6, and IL-1, are elevated in biological 
tissues (synovial fluid, serum, cartilages) (Choy & Panayi, 2001; Tsuchida et al., 2014; 
Ren et al., 2018). These elevated pro-inflammatory cytokine levels are believed to 
contribute to the development of persistent inflammation and, eventually, the 
development of autoimmunity that leads to tissue damage (cartilage and bone) (Kim 
& Moudgil, 2017).  
Administration of neutralizing agents to inhibit inflammatory mediator and NGF 
production has been shown to be beneficial for chronic pain conditions such as CRPS. 
In a case study, Huygen and colleagues (Huygen et al., 2004b) demonstrated the 
effectiveness of anti-TNF (infliximab) in two CRPS patients. Following this treatment, 
the cutaneous levels of TNF and IL-6 were significantly reduced in blister fluid 
Chapter 1. Introduction 
 11 
obtained from the affected limb. In addition, the clinical signs of CRPS and patient 
well-being were improved. In a double-blind, randomized, placebo-controlled trial, 
involving a larger number of CRPS patients, the benefit of anti-TNF was further 
investigated (Dirckx et al., 2013). Although the trial was discontinued due to 
budgetary limitations, the preliminary report showed a trend towards similar benefits 
of anti-TNF in CRPS patients (Dirckx et al., 2013). While anti-NGF has not been 
tested in clinical settings, in a tibia fracture rat model of CRPS, administration of anti-
NGF antibody reduced NGF levels and neuropathic pain behaviour, such as hind paw 
mechanical allodynia and hindlimb unweighting (Sabsovich et al., 2008b; Wei et al., 
2016).  
 
1.5. Cross-talk between the sympathetic nervous system and immune 
system, mediated through 1-adrenoceptors  
There is growing evidence that 1-AR mediate cross-talk between the SNS and the 
immune system. Stimulation of 1-AR modulates immune cell (peripheral blood 
leukocytes, dendritic cells, monocytes, macrophages) functions, such as their 
migration and cytokine production (Heijnen et al., 1996; Maestroni, 2000; Roupe van 
der Voort et al., 2000; Grisanti et al., 2011b). As an example, noradrenaline 
administration to bone-marrow derived dendritic cells (DC) enhances cell migration 
and the effect is stronger in mature DCs compared to immature DCs (Maestroni, 
2000). In vivo, topical administration of the 1-AR antagonist prazosin on a mouse 
ear, but not the -adrenergic antagonist propranolol, inhibits FITC-induced 
(fluorescein isothiocyanate, fluorescence molecules) Langerhans cell (skin DC) 
migration to lymph nodes (Maestroni, 2000). This suggests that sympathetic 
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catecholamine neurotransmitters modulate immune cell migration by acting on the 
1-AR. 
Monocytes play an important role in the innate immune system. Utilizing an in vitro 
approach, Grisanti and colleagues investigated the role of 1-AR in modulating 
monocyte’s responses to lipopolysaccharide (LPS; a gram-negative bacterial cell wall 
component that activates Toll-like receptor 4 (TLR4) in immune cells) in producing 
inflammatory cytokines (Grisanti et al., 2011b). They showed that administration of 
the 1-AR agonist phenylephrine and LPS enhanced IL-1 production from a 
monocyte cell line, THP-1, and human primary monocytes, compared to the cells 
treated with phenylephrine or LPS only. However, the modulatory effect of 
phenylephrine on LPS-induced IL-1 production was blocked in the presence of the 
1-AR antagonist BE2254 (Grisanti et al., 2011b). Further investigation showed that 
the interaction between 1-AR and TLR4 signalling pathways was mediated through 
activation of PKC/p38 MAPK (protein kinase C/p38 MAP kinase).  
Moreover, inflammatory cytokines, such as TNF and IL-1, modulate 1-AR 
expression in immune cells. Resting THP-1 cells express 1B-AR and 1D-AR, without 
any detectable expression of 1A-AR (Rouppe van der Voort et al., 1999). Interestingly, 
administration of inflammatory cytokine TNF or IL-1 to THP-1 cells increases 1A-
AR expression to detectable levels but decreases 1B-AR and 1D-AR expression 
levels (Heijnen et al., 2002). These studies indicate a positive feedback interaction 
between 1-AR and inflammatory cytokines in immune cells, which may be important 
in normal inflammatory processes.  
In healthy control peripheral blood mononuclear cells (PBMCs), the expression of 1-
AR is undetectable (Casale & Kaliner, 1984). However, in chronic inflammatory 
diseases, such as juvenile rheumatoid arthritis (JRA), PBMCs express functional 1-
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AR (Heijnen et al., 1996). Heijnen and colleagues demonstrated that stimulating JRA 
PBMCs with phenylephrine resulted in a significant increase in IL-6 production from 
the cells, while IL-6 production from healthy control PBMCs remained unchanged 
(Heijnen et al., 1996). On the contrary, application of the 1-AR antagonist doxazosin 
inhibited a stimulatory effect of phenylephrine on IL-6 production. This reveals that 
interaction between 1-AR and IL-6 in PBMCs is specifically mediated through 1-AR 
signalling. To investigate the significance of this interaction in vivo, Roupe van der 
Voort and colleagues administered a standardized cold pressor test (CPT; a stressor) 
to JRA patients and healthy controls to induce endogenous catecholamine production, 
which was confirmed by an immediate plasma noradrenaline spike measured within 
1 min after the CPT (Roupe van der Voort et al., 2000). The CPT-induced 
noradrenaline augmented JRA PBMCs’ response to lipopolysaccharide challenge, 
resulting in elevated IL-6 production, while IL-6 production in healthy control PBMCs 
was unaltered (Roupe van der Voort et al., 2000). Investigation into the mechanism 
behind the 1-AR-induced IL-6 production in PBMCs showed that this interaction was 
mediated through activation of extracellular signal regulated kinases (ERKs) (Rouppe 
van der Voort et al., 2000). 
In a canine model of chronic low-grade system of inflammation, administration of daily 
intraperitoneal injection of LPS in dogs for 2 weeks induced protein levels of TNF 
and IL-6 in plasma and right atrial tissues (Chen et al., 2017b). Additional oral 
administration of the 1-AR antagonist doxazosin reduced TNF and IL-6 protein 
levels compared to animals that were treated with LPS only. Moreover, doxazosin 
treatment also reduced NF-B activation, which may indicate the involvement of NF-
B activation in mediating the interaction between 1-AR and inflammatory mediators 
in this in vivo model.   
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Pro-inflammatory cytokines, such as IL-1, IL-6 and TNF, have been suggested to 
mediate the development of depression symptoms. Utilizing an LPS-induced 
depression-like behaviour rat model, Kurosawa and colleagues demonstrated that 
intraperitoneal injection of LPS increased serum IL-1, IL-6 and TNF levels and the 
number of tyrosine-hydroxylase positive neurons (a marker for dopaminergic and 
noradrenergic neurons) around the locus coeruleus (Kurosawa et al., 2016). Further 
investigation revealed that intracerebroventricular injection of IL-1 and IL-6 activated 
tyrosine hydroxylase-positive neurons around the locus coeruleus and led to the 
development of depression-like behaviour. On the contrary, pre-treatment with 
prazosin prior to the intracerebroventricular cytokine injection abolished this 
behaviour. Interestingly, intracerebroventricular injection of phenylephrine alone also 
induced depression-like behaviour in the experimental rats. This suggests that 1-AR 
plays an important role in mediating pro-inflammatory cytokine-induced depression 
symptoms.  
Consumption of addictive stimulant drugs, such as cocaine, has been shown to alter 
the immune system. Specifically, septic complications are often reported among drug 
users. An in vivo experiment using rats demonstrated that intravenous injection of 
cocaine altered cardiovascular function and increased susceptibility to LPS-induced 
inflammation (Knuepfer et al., 2004). In addition, amongst rats with strong vascular 
responses to cocaine, LPS administration post-cocaine treatment resulted in 
heightened pupil dilation and inflammatory cytokine levels (IL-6 and IL-10), and 
ultimately death. However, pre-treatment of prazosin prior to cocaine-LPS 
administration reduced detrimental effects of cocaine on immune responses to 
infection, improved cardiovascular responses to cocaine and enhanced survival.   
Studies have suggested that stressful events may induce inflammatory mediator 
levels and that this involves 1-AR signalling. In an experiment involving human 
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participants, a hypoxic condition induced by high altitude (an environmental stressor) 
significantly increased resting plasma IL-6 levels compared to the levels measured at 
zero altitude (sea-level; (Mazzeo et al., 2001)). Performing high impact exercise (a 
physical stressor) resulted in elevated plasma IL-6 levels, which were higher at high 
altitude compared to sea-level. However, administration of prazosin inhibited the 
stress-induced increase in plasma IL-6. Chronic stress has been shown to enhance 
the progression of periodontitis (a chronic inflammatory disease affecting the gums) 
by inducing 1-AR-mediated inflammatory responses. In a rat model of periodontitis, 
1-AR expression was increased in periodontal tissues and this expression was 
further elevated under chronic stress conditions (Lu et al., 2014). However, blocking 
this 1-AR signalling through perfusion of the non-selective -AR antagonist 
phentolamine reduced LPS-induced inflammatory responses in the periodontal 
tissues. Together, the aforementioned studies support an important role of 1-AR in 
mediating stress-induced inflammatory responses.  
Cross-talk between 1-AR and inflammatory mediators may also play a role in cancer 
progression. In some type of cancers, an increased production of noradrenaline is 
positively correlated with the tumorigenesis and considered to be a risk factor in 
developing cancer (reviewed by (Fitzgerald, 2009)). In addition, chronic inflammation 
induced by excessive inflammatory responses contributes to tumour development 
and carcinogenesis (Karin & Greten, 2005). In patients suffering hepatocellular 
carcinoma (HCC), the density of sympathetic nerve innervations on the tumours 
correlates positively with tumour progression and negatively with disease-free 
survival (Huan et al., 2017). In animal models of chemical-induced HCC, tumour 
progression is also associated with an increased production of inflammatory 
cytokines from Kupffer cells (a resident macrophage in the liver) (Huan et al., 2017). 
In contrast, chemical sympathectomy or administration of the 1-AR antagonist, 
prazosin, prior to inducing HCC, supressed inflammatory cytokine production from 
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Kupffer cells and reduced the tumour size. Recent evidence also shows that 1-AR 
antagonists inhibit cancer cell proliferation and motility in other types of cancers (Lin 
et al., 2007; Assad Kahn et al., 2016; Colciago et al., 2016).  
In other cell types, such as cardiomyocytes and 1A-AR-stably-expressed Rat-1 
fibroblasts, Perez and colleagues demonstrated a positive feedback interaction 
between 1-AR and IL-6 (Perez et al., 2009). Cardiomyocytes obtained from mouse 
pups and Rat-1 fibroblasts were treated with epinephrine (adrenaline) in the presence 
of -AR and 2-AR antagonists, propranolol and rauwolscine, respectively. 
Administration of epinephrine resulted in an increased cellular production of IL-6. 
Moreover, pre-treatment with the 1-AR antagonist prazosin blocked the effect of 
epinephrine on IL-6 levels (Perez et al., 2009). These results suggest that epinephrine 
induces IL-6 production from both cardiomyocytes and Rat-1 fibroblasts by acting 
through 1-AR. Investigations into the mechanisms behind the interaction between 
1-AR and IL-6 showed that stimulation of 1-AR enhanced IL-6 transcription, 
mediated through activation of p38 MAPK and NF-B  (Perez et al., 2009). 
Collectively, the studies mentioned above indicate that cross-talk between 1-AR and 
inflammatory cytokines may be important in normal inflammation. However, 
dysregulation of this cross-talk may alter normal inflammatory processes, which 
subsequently induces an unresolved and persistent inflammatory state.  
An increasing number of studies also indicate that 1-AR-mediated cross-talk 
between the SNS and immune system may be involved in the pathophysiology of 
chronic pain. In particular, in neuropathic pain (a type of chronic pain that arises from 
an injury or disease affecting the nervous system (Treede et al., 2008)), excessive 
inflammation (Huygen et al., 2002; Huygen et al., 2004a; Li et al., 2013; Birklein et al., 
2014) and heightened 1-AR expression are present in the skin of the affected limb 
Chapter 1. Introduction 
 17 
of patients and in neuropathic pain animal models (Drummond et al., 2014a; 
Drummond et al., 2014c; Finch et al., 2014). In the present study, the role of 1-AR 
in mediating cross-talk between the SNS and immune system in complex regional 
pain syndrome (CRPS; a type of neuropathic pain) will be investigated, to determine 
whether this may contribute to the pathophysiological mechanism underlying this 
chronic pain condition. The following sections will review the involvement of the SNS 
and inflammation in the pathogenesis of CRPS, and the possible role of 1-AR in 
mediating cross-talk between the SNS and immune system.    
 
1.6. Complex regional pain syndrome  
Complex regional pain syndrome (CRPS) is a complex and debilitating type of 
neuropathic pain. This condition is debilitating as the pain causes disturbances in 
mobility, sleep and social activity (Smith & Torrance, 2012), frequently leading to the 
development of psychological problems, such as depression, anxiety, and stress 
(Haythornthwaite & Benrud-Larson, 2001). Like other types of neuropathic pain, 
CRPS is mainly characterized by hyperalgesia (an increased sensitivity to a stimulus 
that usually provokes pain – nociceptive stimulus) and allodynia (pain due to a 
stimulus that does not normally provoke pain – non-nociceptive stimulus) (Merskey & 
Bogduk, 1994; Li et al., 2000; Baron et al., 2010). Unfortunately, since the severity of 
pain experience varies between individuals with the same degree of lesion, 
diagnosing neuropathic pain is often difficult. In addition, mechanisms behind 
neuropathic pain are not fully understood, which makes it difficult to provide effective 
targeted treatment for these patients.  
One of the triggers of CRPS is an injury to a limb (Brunner et al., 2017; Savas et al., 
2017). Based on the evidence of major peripheral nerve damage, CRPS is further 
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classified into CRPS type I or type II, in which a lesion to peripheral nerves is absent 
or present, respectively. Although there is no evidence of nerve trunk damage in 
CRPS I, nerve fibre density in the skin is lower than normal (Albrecht et al., 2006; 
Oaklander et al., 2006; Morellini et al., 2018; Rasmussen et al., 2018; Drummond et 
al., 2019). Nevertheless, the burden and the clinical presentations of both CRPS 
types are similar. The first local population-based epidemiological study in 2003 
revealed the incidence of CRPS to be around 6.28 per 100,000 person years (5.46 
per 100,000 person years for CRPS type I  and  0.82 per 100,000 person years for 
CRPS type II) (Sandroni et al., 2003). In 2007, a larger epidemiological study based 
on the Netherlands population updated the incidence rate of CRPS to 26.2 per 
100,000 person years (de Mos et al., 2007). Nevertheless, these figures may be an 
underestimation. As this condition is very debilitating, it is important to clarify the 
pathophysiological mechanisms of CRPS. 
The clinical presentations of CRPS include neuropathic pain behaviours (nociceptive 
hypersensitivity), autonomic dysfunction (swelling, oedema, excessive sweating), 
trophic changes (skin, hair and nail changes), motoric dysfunction (muscle weakness, 
atrophy, contractures). These clinical presentations are included in the Budapest 
criteria, a recent clinical diagnostic tool for CRPS (Harden & Bruehl, 2005; Harden et 
al., 2010b; Harden et al., 2010a). Skin temperature differences are observed between 
the affected and unaffected limb. Additionally, skin colour on the affected limb 
changes between the acute and chronic stages of CRPS. Both of these changes 
indicate vascular disturbances in CRPS. One proposed mechanism underlying 
vascular disturbances in CRPS is SNS dysfunction, mediated through 1-AR. Wasner 
and colleagues demonstrated the loss of sympathetic vasoconstrictor activity in the 
affected limb of CRPS patients at the acute stage (Wasner et al., 1999). This resulted 
in a warmer skin temperature (caused by vasodilation) on the affected limb compared 
to the contralateral site (“warm” CRPS). Moreover, the levels of blood norepinephrine 
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were reduced on the affected site (Wasner et al., 1999). It was hypothesized that the 
loss of cutaneous sympathetic vasoconstrictor activity and the reduction of 
norepinephrine levels at the affected site led to heightened 1-AR expression in the 
blood vessels and increased 1-AR sensitivity to catecholamines. This condition 
results in an increased vasoconstriction and decreased blood flow during sympathetic 
arousal that leads to the development of ‘cold’ CRPS seen in the chronic stage.  
Persistent inflammation is present in the affected limb of CRPS patients, in particular 
in the acute stage of CRPS (Marinus et al., 2011). The pathophysiology of CRPS is 
not fully understood, but growing evidence shows that persistent inflammation and 
disturbances in SNS function in the acute stage of CRPS may contribute to the 
development of the condition into a chronic stage (Schlereth et al., 2014; Knudsen et 
al., 2019). Although inflammation is a normal physiological function designed to 
provide defence mechanisms and initiate healing processes after injury, there is 
evidence to show that inflammation becomes excessive in CRPS, resulting in a 
persistent inflammatory condition (Groeneweg et al., 2006; Heijmans-Antonissen et 
al., 2006; Kramer et al., 2011; Marinus et al., 2011; Birklein et al., 2014). Unfortunately, 
however, the mechanisms underlying this persistent inflammatory condition in CRPS 
are not fully understood. Moreover, whether the SNS dysfunction contributes to the 
development of this persistent inflammation requires further investigation. 
 
1.6.1. Involvement of the sympathetic nervous system in CRPS 
Sympathetic dysfunction contributes to the pathophysiology of CRPS. Sympathetic 
blocks, such as administration of local anaesthetic (Price et al., 1998; Stanton et al., 
2013; O'Connell NE & Carr DB, 2016) or sympathectomy (Singh et al., 2003), have 
been used widely in clinical practice to reduce pain. As an example, stellate ganglion 
blocks have been commonly used as pain management for CRPS (Price et al., 1998; 
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Wei et al., 2014), although only short-term pain relief was achieved in some patients 
(Price et al., 1998; Ackerman & Zhang, 2006; Cheng et al., 2019). This subset of 
CRPS patients is considered to have sympathetically maintained pain. However, due 
to the side effects and complications of sympathetic blocks (Doroshenko et al., 2020) 
and the lack of good quality double blinded, placebo-controlled, and randomized 
studies with sufficient samples size and follow-up period, the safety and efficacy of 
sympathetic blockade as a treatment for CPRS needs to be further validated  (Cepeda 
et al., 2005; Stanton et al., 2013).  
Under normal conditions, SNS activity does not usually affect the nociceptors. 
However, cross-talk between the SNS and sensory neurons may contribute to the 
development of persistent pain in this CRPS subset. Furthermore, studies show that 
this cross-talk occurs through a direct interaction between the two nervous systems 
or an adrenoceptor-mediated interaction (Davis et al., 1991; Chabal et al., 1992; 
Torebjork et al., 1995; Choi & Rowbotham, 1997; Ali et al., 2000; Lee et al., 2000; 
Nam et al., 2000; Mailis-Gagnon & Bennett, 2004).  
A direct coupling between sympathetic and sensory neurons has been demonstrated 
in animal models of neuropathic pain (Chung et al., 1993; McLachlan et al., 1993; 
Janig et al., 1996; Ramer & Bisby, 1997; Xie et al., 2007). Several days following 
nerve injury, abnormal innervations (sprouting) of postganglionic sympathetic fibres 
have been observed surrounding surviving primary afferents in the dorsal root ganglia 
(DRG) supplying the injured nerve. In addition, the extent of axon sprouting increases 
with time (McLachlan et al., 1993). The sympathetic fibre sprouts are also present in 
DRG of patients suffering from persistent neuropathic pain (Shinder et al., 1999). 
Interestingly, the degree of this sprouting is correlated with the severity of neuropathic 
pain behaviours (Chung et al., 1997). It can be postulated that the presence of 
sympathetic nerve sprouts amongst the nociceptors in the DRG may facilitate direct 
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stimulation of nociceptors through neurotransmitters released by sympathetic nerves, 
thus establishing sympathetically maintained pain. 
The adrenoceptor-mediated cross-talk between the SNS and nociceptors has been 
observed in several studies. Electrical stimulation of the SNS or a systemic adrenaline 
injection evoked primary afferent activity in a rat model of neuropathic pain (Devor et 
al., 1994). Similarly, in neuropathic pain patients with sympathetically maintained pain, 
an injection or topical administration of adrenergic ligands has been shown to evoke 
pain (Davis et al., 1991; Chabal et al., 1992; Torebjork et al., 1995; Choi & 
Rowbotham, 1997; Ali et al., 2000). Interestingly, in neuropathic pain patients who 
underwent successful sympathectomy, an intracutaneous injection or iontophoresis 
of noradrenaline into the skin of the symptomatic limb evoked pain similar to the 
original pain (Torebjork et al., 1995). However, administration of adrenergic ligands 
to an unaffected limb or in healthy controls did not induce pain (Choi & Rowbotham, 
1997; Ali et al., 2000). An injection of the -adrenoceptor antagonist phentolamine 
attenuated the excitatory effect of sympathetic stimulation on the DRG, while an 
injection of -adrenoceptor antagonist propranolol, did not show any effects (Devor 
et al., 1994). This demonstrates that the -adrenoceptors, rather than -
adrenoceptors, mediate the SNS-nociceptor coupling in neuropathic pain.  
Studies utilizing a specific agonist and antagonist against -AR types show that 1-
AR, instead of 2-AR, is likely to be the primary mediator in the adrenoceptor-
mediated coupling between the SNS and nociceptors in neuropathic pain (Davis et 
al., 1991; Choi & Rowbotham, 1997; Drummond et al., 2016; Drummond et al., 2018). 
An intradermal injection of the 1-AR agonist phenylephrine to the 
affected/symptomatic limb of CPRS patients with sympathetically maintained pain, 
evoked persistent heightened pain, hyperalgesia and mechano-allodynia, while an 
injection of phenylephrine to a non-affected limb of CRPS patients or healthy people 
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evoked only momentary pain (Davis et al., 1991; Mailis-Gagnon & Bennett, 2004; 
Drummond et al., 2016; Drummond et al., 2018). In addition, pre-treatment with the 
1-AR antagonist prazosin reduced hyperalgesia and allodynia to brushing 
(Drummond et al., 2016). On the other hand, stimulation of 2-AR through its agonist 
clonidine inhibited noradrenaline release and suppressed pain in patients with 
sympathetically maintained pain (Davis et al., 1991; Drummond et al., 2016) thus 
suggesting the analgesic property of 2-AR.  
Heightened expression of 1-AR has been observed following nerve injury and may 
mediate adrenergic sensitivity in primary nociceptive afferents. In a cat model of 
spinal injury, an autoradiographic study using radioligand [3H]-prazosin revealed an 
increase in 1-AR expression in the injured spinal cord, compared to uninjured cats 
(Giroux et al., 1999). In neuropathic pain rat models, gene expressions of 1-AR were 
elevated in the DRG or spinal cord of rats with spinal nerve ligation (Xie et al., 2001), 
sciatic nerve injury (Maruo et al., 2006), or streptozotocin-induced diabetic 
neuropathy (Lee et al., 2000). This heightened 1-AR expression is also observed in 
the skin, where primary afferent nociceptors are abundant. In rat models of 
neuropathic pain, peripheral nerve injury induced a significant increase in 1-AR 
expression in the epidermis or on surviving dermal nerve bundles of the affected limb, 
compared to the contralateral site and sham controls (Drummond et al., 2014a; 
Drummond et al., 2014c). Cutaneous 1-AR upregulation was also observed in the 
epidermis and dermal nerve fibres of the affected limb of patients suffering from 
CRPS (Drummond et al., 2014c; Finch et al., 2014; Drummond et al., 2018). This 
indicates that activation of cutaneous 1-AR may contribute to pain processing in 
CRPS.   
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1.6.2. Evidence of excessive inflammation in CRPS 
In the acute stage of CRPS, the signs of inflammation, such as pain, heat, redness, 
and swelling persist in the affected limb, even after the healing process is complete. 
This may indicate excessive and dysregulated inflammatory responses following 
injury in the acute stage of CRPS that may contribute to the development of this 
condition into a chronic stage (Birklein & Dimova, 2017).  
Gene expression levels and protein production of inflammatory mediators, such as 
TNF, IL-1, IL-6, are significantly increased following experimental nerve injury in 
rats (DeLeo et al., 1996; Wagner & Myers, 1996b; Arruda et al., 1998; Okamoto et 
al., 2001; Pineau & Lacroix, 2007; Üçeyler et al., 2007). In rats that underwent sciatic 
nerve cryoneurolysis, heightened IL-6 expression was found in the ipsilateral (an 
affected site) dorsal horn of the spinal cord up to 35 days post-cryoneurolysis, and 
interestingly, the IL-6 levels were positively correlated with touch-evoked allodynia 
(DeLeo et al., 1996). Similar heightened IL-6 levels were also found at the injured 
nerves of other neuropathic pain rat models, such as spinal nerve cryoneurolysis and 
spinal nerve tight ligation, and these IL-6 levels were associated with touch-evoked 
allodynia (Arruda et al., 1998). A chronic constriction injury to rat sciatic nerves 
resulted in elevated TNF and IL-1 mRNA levels at the injured nerves (Wagner & 
Myers, 1996b; Okamoto et al., 2001; Üçeyler et al., 2007), which were positively 
correlated with thermal hyperalgesia and mechanical allodynia (Okamoto et al., 2001). 
Utilizing immunohistochemistry, TNF-immunoreactivity was found to be increased in 
local resident cells of the injured sciatic nerves, such as endothelial cells, 
macrophages, fibroblasts and Schwann cells (Wagner & Myers, 1996b). 
In rats with tibia fracture as a model for CRPS type I, levels of TNF, IL-6, IL-1, NGF 
were elevated in the hind paw skin of the fractured limb at 4-weeks post-fracture, 
compared to uninjured rats (Li et al., 2009a; Li et al., 2010). In addition, these rats 
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developed neuropathic pain behaviours, such as hind paw mechanical allodynia and 
unweighting. Interestingly, a sub-cutaneous injection of pro-inflammatory mediators, 
such as TNF (Sabsovich et al., 2008a; Li et al., 2010), IL-1 (Li et al., 2009b) , or IL-
6 (Li et al., 2010) to the hind paw of normal rats induced similar neuropathic pain 
behaviour as seen in the fractured rats, while such injection aggravated neuropathic 
pain behaviours when administered locally to injured tissue (DeLeo et al., 1996; 
Schafers et al., 2003; Kim & Moalem-Taylor, 2011). On the contrary, administration 
of TNF antagonist (sTNF-R1; (Sabsovich et al., 2008a)) or IL-1 antagonist (IL-1ra; 
(Li et al., 2009b)) alleviated neuropathic pain behaviours. Immunohistochemistry 
analysis of the ipsilateral hind paw skin revealed that inflammatory mediator mRNA 
and protein expression were significantly increased in keratinocytes.  
Inflammatory mediators, such as TNF and IL-6, were also elevated in the skin and 
skin blister fluid obtained from the symptomatic limb of CRPS patients (Huygen et al., 
2002; Groeneweg et al., 2006; Heijmans-Antonissen et al., 2006; Kramer et al., 2011; 
Birklein et al., 2014), but not in the blood (Huygen et al., 2002; Schinkel et al., 2006; 
Schinkel et al., 2009). Collectively, these animal and human studies suggest that 
cutaneous immune responses may be important as an early response to nerve injury, 
and excessive accumulation of these inflammatory mediators may contribute to 
persistent pain in CRPS. However, the mechanisms behind this persistent cutaneous 
inflammation in CRPS patients are not totally understood.  
 
1.7. Aims and hypotheses  
In this study, the role of 1-AR in mediating the nerve-immune system interaction in 
normal inflammation and in CRPS was investigated, utilizing skin as an experimental 
model. The main cell types coordinating immune functions in the skin include resident 
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structural cells, such as keratinocytes and fibroblasts, that work with resident innate 
immune cells, such as macrophages and Langerhans cells, to orchestrate the local 
inflammatory process (Kuo et al., 2013; Matejuk, 2018). In addition, nociceptors and 
sympathetic nerve fibres innervate the skin layers (Ruocco et al., 2002; Donadio et 
al., 2019), which indicate a possible interaction between the nerves and resident skin 
cells. 
A large body of evidence presented in the above literature review indicates that the 
SNS, mediated through 1-AR, may play a role in cutaneous inflammation. This is 
based on the evidence that keratinocytes, the most abundant cells in the epidermis, 
express 1-AR and produce inflammatory mediators. Moreover, upregulation of 1-
AR expression and heightened production of inflammatory mediators in the skin have 
been observed in several chronic inflammatory diseases and neuropathic pain. 
However, how 1-AR modulates cutaneous inflammation and what causes 1-AR 
upregulation and heightened inflammatory mediator production in pathological 
conditions are not fully understood.  
The overall hypothesis investigated was that inflammatory mediator production by 
keratinocytes in response to an injury act in a feedback loop to up-regulate 1-AR 
expression in these cells. Consequently, this heightened expression of 1-AR could 
increase sensitivity to stimulation, leading to further release of inflammatory 
mediators from keratinocytes, thus establishing a positive feedback interaction. 
Furthermore, it was hypothesized that in keratinocytes derived from CRPS patients, 
this positive feedback loop may be stronger compared to keratinocytes isolated from 
the skin of healthy controls. 
To address these hypotheses, in vitro, in vivo, and ex vivo approaches were used to 
investigate the role of 1-AR in cutaneous inflammation and a possible interaction 
between 1-AR and inflammatory mediators in the skin. An immortalized human 
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keratinocyte cell line (HaCaT) and the prototypical pro-inflammatory cytokine, TNF, 
were used as an in vitro model and to induce an inflammatory state in cultured 
keratinocytes, respectively. In the in vivo approach, a skin microdialysis technique 
was used to determine the effects of 1-AR stimulation in acute skin inflammation, 
induced by UVB irradiation. In addition, primary keratinocytes were obtained from 
CRPS patients and healthy control volunteers to investigate the role of 1-AR in 
modulating inflammation in a neuro-pathological condition.  
The specific aims of the study were: 
1. To determine whether TNF induced 1-AR expression in keratinocytes in vitro 
and to determine if this was restricted to a specific subtype of 1-AR. The results 
of this aim are presented in Chapter 2. 
2. To assess if 1-AR stimulation in activated (TNF-induced) HaCaT cells further 
induced inflammatory mediator production, thus establishing a positive feedback 
interaction between 1-AR and inflammatory mediators in keratinocytes in vitro. 
The results of this aim are presented in Chapter 3. 
3. To investigate the effect of 1-AR stimulation in a UVB-irradiated skin, as an in 
vivo model for acute cutaneous inflammation. The results of this aim are 
presented in Chapter 4. 
4. To investigate the interaction between 1-AR and inflammatory mediators in 
keratinocytes cultured ex vivo from the skin of CRPS patients and healthy control 
volunteers to determine whether the interaction was amplified in CRPS 
keratinocytes compared to healthy control keratinocytes. The results of this aim 
are presented in Chapter 5. 
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Chapter 2. Tumour necrosis factor  induces 1B-
adrenergic receptor expression in keratinocytes 
2.1. Preface 
This chapter has been published as:  
Wijaya LK, Stumbles PA, & Drummond PD (2020) Tumor necrosis factor alpha 
induces alpha1B-adrenergic receptor expression in keratinocytes. Cytokine 125: 
154851. doi:10.1016/j.cyto.2019.154851. 
The copyright is owned by Elsevier Ltd. The numbering system and the references in 
this chapter has been modified from the published manuscript to maintain the 
consistency throughout the thesis. 
 
The role of 1-AR in cutaneous inflammation is not fully understood. Heightened 
cutaneous 1-AR expression and excessive inflammation have been identified in 
some inflammatory diseases and chronic pain, which suggests a potential interaction 
between 1-AR and inflammatory processes in the skin. In this chapter, I present an 
in vitro study that identifies the effects of inflammatory signalling on 1-AR expression 
in keratinocytes, as the first step to investigate this potential interaction. 
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2.2. Abstract 
Keratinocytes produce cytokines and nerve growth factor (NGF) as part of a repair 
response to injury, disease or stress, and express alpha1-adrenoceptors (1-AR). The 
expression of these receptors is elevated in some inflammatory diseases and chronic 
pain conditions. In this study, we investigated whether inflammatory signalling affects 
1-AR expression in keratinocytes in vitro. Tumour necrosis factor  (TNF) was 
administered to human keratinocytes, after which the levels of other key pro-
inflammatory cytokines and NGF were measured. The production of these cytokines 
and NGF increased in cells treated with TNF compared to untreated cells. 
Furthermore, exposure to TNF increased gene expression of the 1-AR subtype B 
in keratinocytes. Our results suggest that inflammatory cytokines released during 
injury stimulate 1-AR expression in keratinocytes. The up-regulation of 1-AR may 
amplify the adrenergic sensitivity of these cells to catecholamines released during 




Cross-talk between the sympathetic nervous system (SNS) and immune system may 
play a role in inflammation. Inflammatory mediators released during inflammation 
modulate the expression of the alpha1-adrenoceptor (1-AR) (a target of the SNS 
neurotransmitter norepinephrine) in a range of cells, including immune cells, 
endothelial cells, and mesangial cells (Bucher et al., 2003). In healthy individuals, 1-
AR expression in peripheral blood mononuclear cells (PBMCs) is undetectable 
(Rouppe van der Voort et al., 1999). However, in chronic inflammatory diseases, such 
as juvenile rheumatoid arthritis, PBMCs express functional 1-AR (Heijnen et al., 
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1996). In addition, stress-induced inflammatory cytokines produced by the PBMCs 
induce 1-AR expression (Roupe van der Voort et al., 2000; Heijnen et al., 2002). As 
a result, the increase in 1-AR expression could further modulate immune cell 
activation, thereby influencing their migration and inflammatory cytokine production 
(Heijnen et al., 1996; Maestroni, 2000).  
We recently found that 1-AR is expressed in epidermal keratinocytes (Dawson et al., 
2011; Finch et al., 2014). These cells make up around 95% of the epidermis and 
provide a barrier to environmental hazards and produce inflammatory cytokines and 
nerve growth factor (NGF). In the present study, we aimed to elucidate further the 
interaction between inflammation and 1-AR in keratinocytes, and to investigate 
whether inflammatory cytokines can trigger 1-AR expression in these cells. We 
utilized tumour necrosis factor  (TNF), a pro-inflammatory cytokine that plays an 
important role in the innate immune response, to induce an inflammatory state in 
keratinocytes. It was hypothesized that TNF, or mediators released during the 
inflammatory cascade induced by TNF, would increase the expression of 1-AR in 
keratinocytes.  
 
2.4. Materials and Methods 
HaCaT cells (a spontaneously immortalized human keratinocytes cell line) (Boukamp 
et al., 1988) were cultured in DMEM media with 10% FBS. Human recombinant TNF 
(PeproTech, USA) was administered to HaCaT cells under reduced-serum conditions 
(0.5% FBS) and incubated for 24 h. Each experimental condition was performed in 
six wells and repeated four times. For the naïve (control) condition, the same media 
without TNF was applied to the cells.  
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A similar experiment was performed in primary human keratinocytes extracted from 
3-mm punch skin biopsies obtained from 4 healthy volunteers (age range 33-55 
years). Each participant provided their informed consent for the procedure, which was 
approved by the Murdoch University human research ethics committee. Primary 
keratinocytes were dissociated from the skin biopsy using the protocol described by 
Aasen and Belmonte (Aasen & Izpisua Belmonte, 2010) and maintained in 
keratinocyte complete media (EpiGro™, Merck, USA).  
Prior to TNF treatment, the media supplements (containing epinephrine, a ligand for 
1-AR) were removed from the culture for 24 h and TNF was applied. HaCaT cells 
and primary keratinocytes were collected and lysed to measure gene expression 
levels of the pro-inflammatory cytokines interleukin (IL)-1, IL-6, IL-8 and NGF, and 
1-AR-subtype B (1B-AR), utilizing a SYBR® green-based qRT-PCR assay, followed 
by melting curve analysis. The mRNA levels of 1-AR-subtype A and D were 
undetectable or beyond the limit of quantification in this qRT-PCR assay (Ct values 
above 33), respectively (unpublished data). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as an endogenous control. All primer sets used 
in this qRT-PCR assay were validated to amplify mRNA-derived transcripts but not 
genomic DNA (unpublished data) and are listed in the supplementary materials 
(Table 2-1; see page 38). A cycle threshold (Ct) value of each sample was collected 
at the end of the qRT-PCR run (40 cycles). The change in gene expression as a result 
of TNF treatment compared to the naïve group was represented by Ct (Yuan et 
al., 2006).  
Protein levels of inflammatory cytokines and NGF secreted by HaCaT cells were 
measured in the media using a multiplex ELISA kit (Bio-Plex Pro™ Human Cytokine 
assay; Bio-Rad Laboratories, USA). These inflammatory cytokines were previously 
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shown to be elevated in chronic neuropathic pain conditions. The assay was 
performed according to the manufacturer’s protocol using undiluted media.  
The mean  SEM of the gene expression changes and the protein levels of four 
biological replicates are presented in the Results. A general linear model with 
repeated measures was applied to determine the effects of TNF on inflammatory 
cytokine, NGF and 1-AR levels. 
 
2.5. Results 
In vitro exposure of HaCaT cells to TNF significantly induced all cytokine mRNA 
levels, along with NGF, at doses of 1 ng/ml and greater, when compared to naïve 
cells (Figure 2-1 A-D). A TNF dose-dependent increase in mRNA expression levels 
was observed for IL-1, IL-8, and IL-6 (Figure 2-1 A-C), but not for NGF, which was 
maximally expressed after exposure to 1 ng/ml TNF (Figure 2-1 D).  
While protein production of IL-1 secreted by HaCaT cells was below the lowest 
detection limit of the kits (0.6 pg/ml – data not shown), TNF increased protein 
production of IL-8, IL-6 and NGF in culture supernatants compared to naïve cells 
(Figure 2-1 E-F). Protein levels of IL-8 were highest amongst the inflammatory 
cytokines after exposure to 50ng/ml TNF (Figure 2-1 E), consistent with mRNA 
expression levels, although a significant increase in IL-8 protein levels was only seen 
for cells that were treated with either 10 or 50 ng/ml TNF (Figure 2-1 E). Increasing 
concentrations of TNF applied to the cells induced significant production of IL-6, with 
IL-6 protein levels increasing in line with increasing levels of TNF at 1 and 10 ng/ml, 
with no further increase at 50 ng/ml TNF (Figure 2-1 F). Compared to IL-8 and IL-6, 
NGF levels showed a less dramatic increase when different concentrations of TNF 
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were administered to the cells, with a significant increase in NGF only observed in 
cells treated with either 10 or 50 ng/ml TNF (Figure 2-1 G).  
To confirm that TNF induced an inflammatory state in primary keratinocytes, 10 
ng/ml TNF was administered to the cells. This dose of TNF increased mRNA levels 
of IL-1, IL-8, and IL-6 (Figure 2-1 A, B, and C, respectively), compared to naïve cells, 
but less strongly than observed in HaCaT cells. However, in contrast to HaCaT cells, 
TNF reduced NGF mRNA levels (Figure 2-1 D).  
Protein concentrations of pro-inflammatory cytokines also increased, but these 
increases did not differ significantly from changes in naïve cells due to wide variation 
in response (Supplementary Materials, Table 2-2; see page 38). NGF protein did not 
change after exposing primary keratinocytes to TNF (Supplementary Materials, 
Table 2-2; see page 38).  
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Figure 2-1. TNF effects on inflammatory cytokine and NGF gene expression 
and protein levels. 
The changes in inflammatory cytokine gene expression levels: (A) IL-1, (B) IL-8, (C) 
IL-6 and (D) NGF, as a result of TNF treatment compared to the naïve condition 
(untreated cells) were represented by Ct (CtNaïve=0). The protein levels of (E) IL-
8, (F) IL-6 and (G) NGF were measured using a multiplex ELISA assay. The bars 
represent mean  SEM of the inflammatory cytokine gene expression and protein 
levels of four independent replicates (represents a significant difference compared 
to naïve, p<0.05; *p<0.05, **p<0.01, ***p<0.001 across different doses of TNF). 
 
 
Exposure to TNF, or inflammatory mediators induced by TNF, significantly 
increased 1B-AR levels in HaCaT cells at 10 or 50 ng/ml TNF compared to the 
naïve condition, while there was no change in 1B-AR mRNA levels in the cells treated 
with the lowest dose of TNF (Figure 2-2 A). Similarly, an exposure to 10 ng/ml TNF 
increased 1B-AR mRNA levels in primary keratinocytes, compared to naïve cells, 
less strongly than seen in HaCaT cells. An agarose gel representing the correct size 
qRT-PCR products of 1B-AR as a single band at 112 bp is shown in Figure 2-2 B 
(grey arrow). Higher 1B-AR gene expression levels in HaCaT cells treated with 10 
ng/ml TNF were confirmed as a thicker band in lane 1 compared to the naïve 
condition in lane 2. As shown in lanes 3 and 4, genomic DNA was not amplified by 
the primer sets as only 55 bp primer-dimer bands remained (Figure 2-2 B, black 
arrow).  
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Figure 2-2. TNF induced mRNA expression levels of 1B-AR in HaCaT cells and 
primary keratinocytes.  
The changes in 1B-AR gene expression levels, as a result of TNF exposure 
compared to naïve, are represented as mean  SEM of the Ct of four independent 
replicates (CtNaïve=0) (A; represents a significant difference compared to naïve, 
p<0.05). A gel view represents 1B-AR (GeneID: ADRA1B) products amplified by the 
primer sets as a single band at 112 bp (B; grey arrow). Lane 1 and 3 represent qRT-
PCR products from HaCaT cells treated with 10ng/ml TNF and its –RT control, 
respectively. Lane 2 and 4 represent qRT-PCR products from naïve HaCaT cells and 
its –RT control, respectively. Lane 5 represents non-template control. The black arrow 
indicates the remaining primer-dimers of qRT-PCR. L=DNA ladder; –RT control=no 
reverse transcriptase control; bp=base pair. 
 
2.6. Discussion 
In this study, we demonstrate that TNF, a pro-inflammatory cytokine, is able to 
induce an inflammatory state in cultured keratinocytes, marked by increases in 
protein and/or mRNA expression for the key pro-inflammatory cytokines IL-1, IL-6, 
IL-8 and NGF. In addition, TNF, or a TNF-induced inflammatory state, was able to 
upregulate 1B-AR gene expression levels in keratinocytes. Previous studies have 
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shown differential effects of inflammatory cytokines on 1-AR subtype expression in 
several cell types (Heijnen et al., 2002; Bucher et al., 2003) but, to our knowledge, 
this is the first study to show that inflammatory cytokines modulate 1-AR expression 
in keratinocytes.  
In a study by Heijnen and colleagues, administration of inflammatory cytokines to 
human monocytic cells resulted in a concentration-dependent increase in 1A-AR 
expression, while 1D-AR expression decreased and there was no change in 1B-AR 
expression (Heijnen et al., 2002). In primary human endothelial cells collected from 
umbilical veins, the expression of 1B-AR decreased significantly in the presence of 
inflammatory cytokines (Heijnen et al., 2002). A similar reduction in 1B-AR 
expression was seen in cultured mesangial cells (Bucher et al., 2003). This contrasts 
with our results showing that inflammatory cytokines increased 1B-AR expression in 
HaCaT cells and primary keratinocytes. This discrepancy indicates that changes in 
expression of 1-AR subtypes in response to inflammatory cytokine stimuli is cell-type 
specific (Heijnen et al., 2002; Bucher et al., 2003). Moreover, TNF increased 1B-
AR expression in primary keratinocytes less strongly than in HaCaT cells. The short 
lifespan of primary keratinocytes in culture may render these cells less responsive to 
exogenous TNF than HaCaT cells. Moreover, the removal of media supplements 
from primary keratinocyte cultures may slow down cell proliferation. As a result, lesser 
inflammatory cytokines and NGF were produced by the cells, in particular NGF, as a 
normal proliferative stage is necessary for TNF-induced NGF secretion from 
keratinocytes. While there is still limited knowledge about how TNF or inflammation 
regulates 1-AR expression, possible mechanisms may be mediation through 
involvement of NF-B, MAP kinases, and JAK/STAT signalling pathways, which are 
activated after TNF binds to its receptor. Activation of the NF-B pathway down-
regulates 1-AR expression during sepsis (Schmidt et al., 2009), but whether 
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activation of the other signalling pathways can stimulate 1-AR expression in 
keratinocytes is unknown. 
Modulation of 1-AR by inflammatory cytokines and NGF plays an important role in 
wound healing, by influencing fibroblast proliferation and migration and secretion of 
the extracellular matrix needed for repair and remodelling (Liao et al., 2014). In 
addition, cytokines released by keratinocytes may stimulate 1-AR in immune cells to 
migrate and further release inflammatory cytokines to help with the healing process 
(Heijnen et al., 1996; Maestroni, 2000; Roupe van der Voort et al., 2000). While the 
interaction between 1-AR and inflammatory cytokines helps in healing and repair, 
unresolved inflammatory processes mediated through 1-AR may play a role in the 
maintenance of some chronic pain conditions (Schlereth et al., 2014) and the 
pathophysiology of some diseases (Heijnen et al., 1996; Pongratz & Straub, 2014). 
In conclusion, our results show that TNF can induce the release of pro-inflammatory 
cytokines from an immortalized human keratinocyte cell line, and can induce the 
expression of 1B-AR both in these cells and in primary human keratinocytes. Hence, 
inflammatory cytokines released by keratinocytes in response to injury may induce 
the expression of 1B-AR in keratinocytes in vivo. Such increase may heighten the 
response of keratinocytes to catecholamines released by the sympathetic nervous 
system after injury which, in turn, might amplify the inflammatory response. Such a 
cycle, if unresolved, could lead to persistent inflammation as observed in chronic 
disease conditions. Further studies utilizing primary keratinocytes, isolated from 
patients or animal disease models, may provide further insight into the effect of 
inflammatory cytokines on α1-AR expression in pain models and disease. 
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2.7. Supplementary Materials 
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97 
GAPDH NM_002046 5'-GGG TGT GAA CCA TGA GAA-3' 





NM_000679 PrimePCR SYBR Green Assay (assay ID: qHsaCIP0030605). 112 
 
Table 2-2. Inflammatory cytokine and NGF protein levels in primary 
keratinocytes post-TNF treatment at 10 ng/ml (Mean ± SEM). 
Analytes*) Naïve 10ng/mL TNF p value#) 
IL-1 8.20 ± 6.17 13.34 ± 9.61 0.24 
IL-8 467.44 ± 349.89 994.67 ± 557.55 0.17 
IL-6 1829.34 ± 653.41 3942.50 ± 1410.89 0.08 
NGF 0.96 ± 0.65 0.99 ± 0.52 0.89 
*) A different multiplex ELISA kit was used to measured cytokine and NGF protein 
levels in primary keratinocytes (Milliplex MAP Human Adipocytes kit, Merck, USA). 
This kit has higher sensitivity assay for IL-1 compared to the multiplex ELISA kit 
used in HaCaT cells. 
#) Statistical analysis was performed using a paired t-test 
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Chapter 3. A positive feedback loop between alpha1-
adrenoceptors and inflammatory cytokines in 
keratinocytes 
3.1. Preface 
This following is a published paper:  
Wijaya LK, Stumbles PA, & Drummond PD (2020) A positive feedback loop between 
alpha1-adrenoceptors and inflammatory cytokines in keratinocytes. Exp Cell Res 
391(2): 112008. doi:10.1016/j.yexcr.2020.112008.  
The copyright is owned by Elsevier Ltd. The numbering system and the references in 
this chapter has been modified from the published manuscript to maintain the 
consistency throughout the thesis. 
 
Chapter 2 reveals that pro-inflammatory mediator TNF or a TNF-induced 
Inflammatory state increased 1-AR expression in cultured keratinocytes. In Chapter 
3, the consequences of heightened 1-AR expression are further investigated to 
determine whether a positive feedback mechanism between 1-AR and inflammatory 
mediators, as seen in immune cells, may also be present in keratinocytes. Identifying 





Chapter 3.  A positive feedback loop between 1-AR and inflammatory cytokines 
 42 
3.2. Abstract 
A positive feedback loop between inflammatory cytokines and alpha1-adrenoceptors 
(1-AR) (a target of the sympathetic nervous system neurotransmitter norepinephrine) 
influences inflammatory responses in immune cells. This cross-talk between the 
sympathetic nervous system and immune system may play a role in promoting 
chronic inflammation. Emerging evidence shows that 1-AR interact with 
inflammatory cytokines in keratinocytes, and this epidermal adrenergic signalling may 
contribute to skin inflammatory responses following injury, disease or stress. In this 
study, utilizing an in vitro approach, we hypothesized that 1-AR interact in a positive 
feedback loop with inflammatory mediators in keratinocytes. The pro-inflammatory 
cytokine tumour necrosis factor  (TNF) was used to induce an inflammatory state 
in cultured keratinocytes. TNF increased interleukin (IL)-1, IL-6, IL-8 and nerve 
growth factor (NGF) production and gene expression levels of 1-AR subtype B (1B-
AR). Additional stimulation of 1-AR further increased IL-6 levels, while maintaining 
high levels of IL-8 and decreasing levels of IL-1 and NGF. Our results suggest that 
reciprocal influences between 1-ARs and inflammatory cytokines may play a role in 
normal inflammatory responses. However, if unchecked, this cycle could contribute 
to pathology (e.g. chronic inflammatory diseases, chronic pain conditions, and stress-
induced cancer progression). 
 
3.3. Introduction  
Inflammation is a complex biological response to injury, stress or disease which 
promotes immune responses and assists repair and regeneration. Immune cells and 
other local tissue cells, such as keratinocytes in the skin, generate inflammatory 
responses through the release of inflammatory cytokines and growth factors (Bernard 
Chapter 3.  A positive feedback loop between 1-AR and inflammatory cytokines 
 43 
et al., 2012; Shi et al., 2013; Birklein et al., 2014). The sympathetic nervous system 
(SNS) interacts with the immune system in regulating homeostasis of inflammatory 
processes (see reviews by (Janig, 2014; Pongratz & Straub, 2014)). Adrenoceptors 
(ARs) mediate SNS functions and are targets for catecholamines released by the 
SNS during injury or stress. The alpha1-adrenoceptor (1-AR) is a member of the 
adrenoceptor family and is expressed mainly in smooth muscles. Thus, the classical 
role of 1-AR is to modulate smooth muscle contraction. Recent studies show, 
however, that 1-AR are not limited to smooth muscles but are also expressed in 
other cell types, including immune cells (Heijnen et al., 1996; Ricci et al., 1999), 
mesangial cells of kidney (Bucher et al., 2003), keratinocytes (Dawson et al., 2011; 
Li et al., 2013; Finch et al., 2014) and peripheral nociceptive neurons (Dawson et al., 
2011). These findings have led to emergent studies investigating novel roles of 1-
AR in different tissues.  
In immune cells, signalling through 1-AR regulates physiological functions including 
migration and differentiation, and the production of inflammatory cytokines (Heijnen 
et al., 1996; Maestroni, 2000; Roupe van der Voort et al., 2000; Grisanti et al., 2011b). 
While the expression of 1-AR is undetectable in peripheral blood mononuclear cells 
(PBMCs) of healthy control volunteers, PBMCs in patients with juvenile rheumatoid 
arthritis (JRA – a chronic inflammatory and autoimmune disease) express functional 
1-AR. Stimulation of 1-AR by norepinephrine released during cold-pressor stress 
induces elevated production of inflammatory cytokines IL-6 and IL-8 in JRA PBMCs 
compared to PMBCs from healthy people (Roupe van der Voort et al., 2000). In 
addition, inflammatory cytokines released during inflammation induce the expression 
of 1-AR in immune cells (Heijnen et al., 2002). Thus, reciprocal interactions between 
inflammatory cytokines and 1-AR in immune cells may modulate inflammatory 
responses in JRA.  
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Growing evidence suggests that 1-AR signalling in the skin may regulate normal 
inflammatory processes and wound healing. Elevated levels of 1-AR are expressed 
in rat keratinocytes after injuries such as a burn (Drummond et al., 2015), nerve injury 
(Drummond et al., 2014a; Drummond et al., 2014c) or fracture (Drummond et al., 
2014b), possibly due to inflammatory cytokines released by local tissue after injury. 
We recently reported that the pro-inflammatory cytokine tumour necrosis factor  
(TNF) induced inflammatory cytokine and NGF production in a human keratinocyte 
cell line, HaCaT cells, and in cultured primary human keratinocytes (Wijaya et al., 
2020b). Moreover, TNF, or a TNF-induced inflammatory state, evoked 1-AR 
subtype B (1B-AR) expression in these cells. However, whether further stimulation 
of 1-AR in these activated (TNF-treated) keratinocytes promotes further pro-
inflammatory cytokine release is unknown. 
In the present study, we aimed to investigate the effect of 1-AR stimulation on 
inflammatory cytokine and nerve growth factor (NGF) production in normal and TNF-
activated keratinocytes. It was hypothesized that TNF would upregulate 1-AR 
expression on keratinocytes, and that subsequent stimulation of 1-AR would further 
increase the production of a range of inflammatory cytokines and also NGF in these 
cells.  
 
3.4. Material and Methods  
3.4.1. Cell maintenance  
The materials used for maintenance of the cells were purchased from GibcoTM 
(Thermo Fisher Scientific, MA, USA), unless otherwise stated. The immortalized 
human keratinocyte cell line (HaCaT cells) was obtained from the German Cancer 
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Research Centre (DKFZ, Heidelberg, Germany; Cat No. 300493) (Boukamp et al., 
1988). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM), 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Serana, Bunbury, 
Australia) and maintained in a controlled incubator at 37oC with 5% CO2. For the 
experiment, HaCaT cells were plated in a 24-well cell culture plate at 50,000 cells/well 
overnight prior to TNF administration. The cells reached approximately 50-60% 
confluence on the treatment day. 
 
3.4.2. TNF treatments and 1-AR stimulation 
All treatments were performed in DMEM under reduced-serum conditions (0.5% FBS) 
to minimise the effect of cell proliferation and growth on 1-AR expression (Gonzalez-
Cabrera et al., 2004). Human recombinant TNF (Peprotech, New Jersey, USA) was 
administered to HaCaT cells at 10 ng/ml and incubated for 24 h. We have previously 
shown that 10 ng/ml TNF administered to HaCaT cells for 24 h significantly 
increases inflammatory cytokine and NGF production (Wijaya et al., 2020b). A 
selective agonist of 1-AR, phenylephrine (Sigma-Aldrich, NSW, Australia), was 
applied to the cells at a final concentration of 1 or 10 M for 6 h, following TNF 
treatments. The naïve cells were treated with media only. Cells that were treated with 
either TNF or phenylephrine only, along with the naïve condition, were used as 
experimental controls. Each experimental condition was performed in six wells (six 
technical replicates) and each set of experiments was repeated four times. At the end 
of the experiment, media was collected to measure protein levels of inflammatory 
agents and the cells were rinsed with Hank’s balanced salt solution and lysed with 
lysis buffer supplemented with 0.05% -mercaptoethanol (Aurum total RNA mini kit, 
Bio-Rad Laboratories, CA, USA). The cell lysates from the technical replicates were 
pooled prior to RNA isolation.   
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3.4.3. 1-AR blockade 
To determine whether the effects of 1-AR stimulation on inflammatory cytokine levels 
were mediated specifically through the 1-AR receptor, a selective 1-AR inverse 
agonist, prazosin (Sigma-Aldrich, NSW, Australia), was administered to HaCaT cells 
prior to 1-AR stimulation with phenylephrine. Prazosin was administered to the cells 
at 1 M for 1 h, followed by phenylephrine treatment at 10 M for 6 h. Cells treated 
with media only (naïve), prazosin or phenylephrine only were used as experimental 
controls. Each experimental condition was performed in six wells (six technical 
replicates) and each set of experiments was repeated four times. The effects of 1-
AR blockade on inflammatory cytokine and 1-AR levels were determined through 
gene expression analysis.  
 
3.4.4. Quantitative real-time PCR  
Total RNA was extracted from the cell lysates according to the manufacturer’s 
protocol (Aurum total RNA mini kit, Bio-Rad Laboratories, CA, USA). The amount 
of total RNA was determined using a NanoDrop 2000c UV-Vis Spectrophotometer 
(Thermo Fisher Scientific, MA, USA). One g total RNA was converted to cDNA using 
iScript™ Reverse Transcription Supermix (Bio-Rad Laboratories, CA, USA), with the 
following cycle: 5 min priming step at 25oC, followed by a reverse transcription step 
at 42oC for 30 min and reverse transcriptase inactivation at 95oC for 5 min. A SYBR® 
Green-based quantitative real-time PCR (qRT-PCR) assay was used to measure 
gene expression levels of 1-AR-subtype B (1B-AR) and of the inflammatory 
cytokines interleukin (IL)-1, IL-6, IL-8 and NGF. We previously showed that HaCaT 
cells do not express 1-AR-subtype A (1A-AR) and have a very low expression of 1-
AR-subtype D (1D-AR), beyond the limit of quantification in qRT-PCR (Ct value 
above 33) (Wijaya et al., 2020b). The primer sets used in qRT-PCR are listed in Table 
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3-1. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an 
endogenous control. All of the primers were validated to amplify mRNA-derived 
transcripts but not genomic DNA (unpublished data). The qRT-PCR assay was 
performed using a ViiA™ 7 Real-Time PCR System (Applied BiosystemsTM; Thermo 
Fisher Scientific, MA, USA). A cycle threshold (Ct) value of each sample was 
collected at the end of the qRT-PCR run (40 cycles). Changes in gene expression as 
a result of the treatments compared to the naïve group were represented in Ct, 
where Ct=(Ctnaïve–Cttreatment), Ctnaïve=(Ctnaïve–CtGAPDH), and 
Cttreatment=(Cttreatment–CtGAPDH) (Yuan et al., 2006; Schmittgen & Livak, 2008). The 
mean  SEM of the gene expression changes between biological replicates is 
presented in the Results section. 
 







‘5 – 3’ 
Reverse Sequence 





NM_000584 ATG ACT TCC AAG CTG GCC GT TCC TTG GCA AAA CTG CAC CT 82 
IL6 
(IL-6) 
NM_000600 AGC CCT GAG AAA GGA GAC ATG ACC AGG CAA GTC TCC TCA TTG 144 
IL1B 
(IL-1) 
NM_000576 CTG TCC TGC GTG TTG AAA GA TTG GGT AAT TTT TGG GAT CTA CA 70 
NGF 
(NGF) 
NM_002506 TGT GAT CAG AGT GTA GAA CAA CA CGG ACC CAA TAA CAG TTT TAC C 97 
GAPDH NM_002046 GGG TGT GAA CCA TGA GAA GAC TGT GGT CAT GAG TCC T 136 
ADRA1B 
(1B-AR) 
NM_000679 PrimePCR SYBR Green Assay (assay ID: qHsaCIP0030605). 112 
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3.4.5. Multiplex enzyme-linked immunosorbent assay  
Conditioned media collected from technical replicates were pooled prior to the 
measurement of inflammatory cytokine and NGF protein levels. A magnetic-bead 
based multiplex enzyme-linked immunosorbent assay (ELISA) technology that allows 
simultaneous measurement of different proteins (analytes) in one assay was used to 
quantify the protein levels. Several important inflammatory cytokines that were 
previously shown to be elevated in chronic neuropathic pain conditions were chosen 
from the Bio-Plex Pro™ Human Cytokine assay (Bio-Rad Laboratories, CA, USA) 
(Heijmans-Antonissen et al., 2006; Uceyler et al., 2010; Kramer et al., 2011; Birklein 
et al., 2014). These cytokines were IL-1, IL-6, IL-8 (Bio-Plex Pro™ Human Cytokine 
Group I) and NGF (Bio-Plex Pro™ Human Cytokine Group II). The validation data 
provided by the company has shown no cross-reactivity between the analytes. The 
assay was performed according to the manufacturer’s protocol using undiluted media, 
and the assay signal was measured with a Bio-Plex® 200 System (Bio-Rad 
Laboratories, CA, USA). 
 
3.4.6. Statistical analysis 
A general linear model with repeated measures statistical analysis was applied to 
determine the effects of TNF and phenylephrine on inflammatory cytokine, NGF and 
1-AR gene expression levels. The Ct value was used as the dependent variable 
in the gene expression statistical analysis (Yuan et al., 2006). The values generated 
from the multiplex ELISA assay were analysed to determine the effects of TNF and 
phenylephrine on inflammatory cytokine and NGF protein levels. All statistical 
analysis was performed using SPSS® statistical analysis software version 24 (IBM, 
New York, USA). 
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3.5. Results  
3.5.1. Differential effects of 1-AR stimulation on inflammatory cytokine and 
NGF mRNA levels in HaCaT cells 
In line with our previous findings, 10 ng/ml TNF induced a significant increase in 
pro-inflammatory cytokine (Figure 3-1 A-C) and NGF (Figure 3-1 D) mRNA levels in 
HaCaT cells compared to the naïve condition (Wijaya et al., 2020b). Following TNF 
treatment, stimulation of 1-AR through its agonist phenylephrine (PE) at 1 or 10 M, 
significantly reduced IL-1 mRNA levels, while there was no change in IL-1 levels in 
cells that were only treated with PE (Figure 3-1 A). There was no effect of 1-AR 
stimulation on IL-8 mRNA levels (Figure 3-1 B). Importantly, PE induced IL-6 gene 
expression in the cells that were treated with PE alone when compared to the naïve 
condition and this expression was further increased in the cells administered with both 
TNF and PE, compared to the cells treated with TNF only (Figure 3-1 C). In 
contrast, PE significantly reduced NGF mRNA levels in the cells pre-treated with or 
without TNF, compared to TNF-treated cells only or cells in the naïve condition, 
respectively (Figure 3-1 D). The effects of 1 M PE on inflammatory cytokine and 
NGF gene expression levels were similar to those of 10 M PE (Figure 3-1). 
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Figure 3-1. The effects of TNF and phenylephrine treatments on inflammatory 
cytokine and NGF mRNA levels in HaCaT cells.  
TNF was administered to HaCaT cells at 10 ng/ml in reduced serum media for 24 h. 
Following TNF administration, the 1-AR agonist phenylephrine (PE) was added to 
the cells at a final concentration of 1 or 10 M and incubated for another 6 h. PE alone 
at 1 or 10 M was administered to untreated cells as an experimental control. Naïve 
cells treated with media only were used to estimate baseline expression level. Gene 
expression levels of inflammatory cytokines: (A) IL-1, (B) IL-8, (C) IL-6 and (D) NGF 
were measured. Changes in gene expression as a result of the treatments compared 
to the naïve condition are represented as Ct (CtNaïve=0). Data are represented 
as mean  SEM of four independent replicates (*represents a significant difference 
compared to naïve, p<0.05; represents a significant difference compared to PE-
treated cells only at the same PE concentration, p<0.05; #represents a significant 
difference compared to TNF-treated cells, p<0.05). 
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3.5.2. Phenylephrine reduces 1B-AR mRNA levels in HaCaT cells  
Exposure of HaCaT cells to 10 ng/ml TNF for 24 h increased 1B-AR mRNA levels 
significantly compared to the naïve condition (Figure 3-2). Specific stimulation of 1-
AR with PE resulted in a significant reduction in 1B-AR mRNA levels, both in the 
presence and absence of TNF (Figure 3-2). The effect of PE on the reduction 1B-




Figure 3-2. The effects of TNF and phenylephrine treatments on 1B-AR mRNA 
levels in HaCaT cells.  
Gene expression levels of 1B-AR in HaCaT cells were determined using qRT-PCR. 
Different treatments of either 10 ng/ml TNF, 1 M phenylephrine (PE), 10 M PE, 
or combinations of TNF and PE were applied to HaCaT cells. Naïve cells that were 
treated with media only were used to estimate baseline expression level. Changes in 
gene expression as a result of the treatments compared to the naïve group are 
represented as Ct (CtNaïve=0). Data are represented as mean  SEM of the Ct 
of four independent replicates (*represents a significant difference compared to naïve, 
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p<0.05; represents a significant difference compared to PE-treated cells only at the 
same PE concentration, p<0.05; #represents a significant difference compared to 
TNF-treated cells, p<0.05). 
 
3.5.3. Stimulation of 1-AR, following TNF treatment, further increases IL-6 
protein levels in HaCaT cells   
Inflammatory cytokine and NGF protein levels secreted from HaCaT cells were 
measured from the conditioned media using multiplex ELISA kits. The levels of IL-1 
secreted by HaCaT cells were below the lowest detection limit of the kits (0.6 pg/ml – 
data not shown). The results for IL-8, IL-6 and NGF are presented in Figure 3-3. TNF 
treatment to HaCaT cells significantly increased IL-8 (Figure 3-3 A), IL-6 (Figure 3-
3B) and NGF (Figure 3-3 C) protein levels. There were no effects of PE stimulation 
on IL-8 protein levels (Figure 3-3 A), consistent with the IL-8 mRNA levels (Figure 3-
1 B). PE treatment to naïve cells resulted in an upward trend in IL-6 protein levels 
compared to the naïve condition. Of particular note, following TNF treatment, 
stimulation of 1-AR with 10 M PE resulted in a further significant increase in IL-6 
protein levels, compared to cells treated with TNF only (Figure 3-3 B). While NGF 
mRNA levels were significantly reduced in cells that were treated with PE (Figure 3-
1 D), phenylephrine did not influence NGF protein levels (Figure 3-3 C). 
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Figure 3-3. The effects of TNF and phenylephrine treatments on inflammatory 
cytokine and NGF protein levels in HaCaT cells.  
Inflammatory cytokine and NGF protein produced by HaCaT cells post-TNF and 
phenylephrine (PE) stimulation were measured in the conditioned media using 
multiplex ELISA. TNF was administered to the cells at 10 ng/ml for 24 h, while the 
naïve cells were treated with media only. PE was administered to the cells with or 
without pre-treatment of TNF, at a final concentration of 1 or 10 M PE for another 
6 h. Data are represented as mean  SEM of the four independent replicates 
(*represents a significant difference compared to naïve, p<0.05; represents a 
significant difference compared to PE-treated cells only at the same PE concentration, 
p<0.05; #represents a significant difference compared to TNF-treated cells, p<0.05). 
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3.5.4. 1-AR signalling specifically modulates IL-6 production in HaCaT cells  
To confirm that 1-AR signalling specifically modulated IL-6 levels in HaCaT cells, the 
1-AR selective inverse agonist prazosin (PZ) was used to competitively block 1-AR 
signalling prior to 1-AR stimulation. The changes in both IL-6 mRNA and protein 
levels were investigated. There was a consistent increase in IL-6 mRNA (Figure 3-4 
A) and protein levels (Figure 3-4 B) in HaCaT cells treated with PE, compared to 
naïve cells. Pre-treatment with 1 M PZ prior to 1-AR stimulation with 10 M PE 
resulted in a trend towards decreasing levels of IL-6 mRNA (a reduction in IL-6 mRNA 
levels with pre-treatment of PZ was observed in three of four biological replicates) 
(Figure 3-4 A). At the protein level, there was a significant inhibitory effect of PZ on 
IL-6 production, compared to cells that were treated with PE only (Figure 3-4 B). This 
confirmed that signalling through 1-AR can modulate IL-6 production in keratinocytes. 
PE treatment significantly reduced 1B-AR mRNA levels compared to the naïve 
condition, but pre-treatment with PZ prior to PE did not alter this effect (Figure 3-4 C). 
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Figure 3-4. The effect of 1B-AR blockade on PE-induced IL-6 levels and 1B-AR 
expression in HaCaT cells.  
To investigate whether 1B-AR mediates the effect of phenylephrine (PE) stimulation 
on IL-6 levels, the 1-AR selective inverse agonist prazosin (PZ) was pre-
administered to HaCaT cells prior to PE stimulation, at 1 M for 1 h. PE was then 
added at a final concentration of 10 M for a further 6 h. Naïve cells treated with 
media only were used to estimate baseline expression level. Cells treated either with 
PZ or PE only were used as a comparison. The gene expression levels of IL-6 (A) 
and 1B-AR (C) were determined by qRT-PCR analysis, while IL-6 protein levels (B) 
were measured by ELISA. Changes in gene expression as a result of any treatment 
compared to the naïve condition were represented as Ct (CtNaïve=0). Data are 
represented as mean  SEM of the Ct (n=4) and of the IL-6 protein levels (n=3) 
(*represents a significant difference compared to naïve, #represents a significant 
difference compared to PE-treated cells, represents a significant difference 
compared to PZ-treated cells, p<0.05).    
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3.6. Discussion 
In this study, the effects of 1-AR stimulation in both normal and activated (TNF 
treated) keratinocytes were examined in vitro, and a positive feedback interaction 
between 1-AR and levels of the inflammatory cytokine IL-6 was found. Consistent 
with our previous findings, the pro-inflammatory cytokine TNF induced an 
inflammatory state in cultured HaCaT keratinocytes, characterised by a significant 
increase in production of key pro-inflammatory cytokines and NGF (Wijaya et al., 
2020b). In addition, this inflammatory state upregulated 1B-AR mRNA levels in these 
cells. Stimulation of 1-AR, following TNF treatment, resulted in differential effects 
on inflammatory cytokine and NGF levels in HaCaT cells. Specifically, we showed 
that stimulation of 1-AR in activated keratinocytes resulted in a further increase in 
IL-6 levels, thus potentially establishing a positive feedback loop.  
Levels of IL-1 mRNA decreased in response to the combined TNF and 
phenylephrine treatment, compared to cells treated with TNF only. In contrast, Li 
and colleagues showed that 1-AR stimulation through its agonist cirazoline 
increased the production of IL-1 mRNA in rat keratinocytes compared to untreated 
cells (Li et al., 2013). One possible explanation for this discrepancy is that, in our 
system, TNF stimulated IL-1 expression levels to reach a ceiling and further 
stimulation of 1-AR in these activated cells downregulated IL-1 mRNA levels, in 
order to maintain cell homeostasis (Zhu & Kanneganti, 2017). However, as this does 
not account for the downward trend in IL-1 mRNA levels after treatment with 
phenylephrine alone, this requires further investigation. In addition to its 1-AR 
agonist properties, cirazoline is a nonselective antagonist to 2-AR (Ruffolo & 
Waddell, 1982). Further work is required to determine whether effects at the 2-AR 
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explain the positive effect of cirazoline on IL-1 production in rat keratinocytes (Li et 
al., 2013). 
Phenylephrine did not change mRNA or protein levels of IL-8 either in normal or 
activated keratinocytes. This indicates that IL-8 levels in these cells are regulated 
through inflammatory signalling pathways independently of cross-talk with 1-AR. In 
a human monocyte cell line, THP-1, complex cross-talk between 1-AR and 
inflammatory signalling pathways was shown (Grisanti et al., 2011a). 1-AR 
stimulation increased IL-8 protein levels slightly in THP-1 cells, but when 
inflammatory responses were induced by lipopolysaccharide (LPS), stimulation of 1-
AR reduced LPS-induced IL-8 protein production compared to cells treated with LPS 
only.  
NGF is an important neurotrophin that supports neuronal growth and prevents 
neuronal death. After injury, NGF produced by peripheral tissue promotes peripheral 
nerve regeneration and axonal outgrowth (Gaudet et al., 2011). Prolonged stimulation 
of ARs in myocardial tissue triggers a reduction in NGF levels and results in 
sympathetic nerve loss and heart failure (Kaye et al., 2000; Kimura et al., 2010). The 
reduction in NGF mRNA is reversed through pre-administration of prazosin (Kaye et 
al., 2000). In this study, 1-AR stimulation reduced NGF mRNA levels both in normal 
and activated keratinocytes. However, NGF protein levels remained unchanged, 
possibly due to the stability of NGF protein in culture. Correlation between 
transcription and translation processes depends on factors such as mRNA and 
protein stability and the degree of post-translational modification of proteins. In 
contrast to NGF, transcription and translation processes appeared to operate in 
tandem for other cytokines, as expressed and secreted interleukin levels changed in 
parallel after the TNF and phenylephrine treatments. In vivo, a reduction in skin NGF 
levels may hinder peripheral nerve regeneration and axonal growth after injury. A 
Chapter 3.  A positive feedback loop between 1-AR and inflammatory cytokines 
 58 
reduction in cutaneous nerve fibre density has been identified in skin biopsies 
collected from patients with painful conditions including diabetic neuropathy (Quattrini 
et al., 2008), small nerve fibre neuropathy (Uceyler et al., 2010), leprosy (Facer et al., 
2000), chronic postsurgical sciatica (Drummond et al., 2019) and complex regional 
pain syndrome (Oaklander et al., 2006; Morellini et al., 2018; Rasmussen et al., 
2018). It may be relevant that some of these conditions are associated with an 
upregulation of 1-AR (Drummond et al., 2014c; Finch et al., 2014; Drummond et al., 
2019). 
Growing evidence shows cross-talk between 1-AR signalling and IL-6 levels in 
different cell types and tissues (Li et al., 2013; Huan et al., 2017; Rossi et al., 2018). 
In a study by Perez and colleagues, 1-AR stimulation increased IL-6 levels in mouse 
cardiomyocytes and in 1A-AR-over-expressed rat fibroblasts. This response was 
mediated through a stabilization of IL-6 mRNA and a maintenance of IL-6 
transcription factor, involving the p38 MAPK and NF-B inflammatory signalling 
pathways (Perez et al., 2009). Activation of these pathways triggers inflammatory 
signalling cascades and leads to production of pro-inflammatory cytokines (Zarubin 
& Han, 2005; Liu et al., 2017). In this study, cross-talk between 1-AR signalling and 
IL-6 levels in keratinocytes was demonstrated. In keratinocytes not exposed to TNF 
treatment, 1-AR stimulation induced IL-6 production and this increase was reduced 
by pre-treatment with the 1-AR antagonist prazosin. Interestingly, stimulation of 1-
AR following TNF treatment further increased both mRNA and protein levels of IL-
6. We postulate that TNF activated inflammatory signalling pathways, such as NF-
B, JAK-STAT, and MAPK, to induce IL-6 production (Tanabe et al., 2010). 
Subsequently, stimulation of 1-AR stabilized the production of IL-6 mRNA induced 
through TNF signalling pathways and maintained transcription factors for IL-6 
activated through TNF-induced NF-B and MAPK pathways (Perez et al., 2009). This 
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cross-talk between 1-AR and inflammatory signalling pathways may trigger 
overproduction of IL-6, and dysregulation of this interaction could maintain 
inflammatory conditions in keratinocytes. Although this seems plausible, further 
studies are required to confirm that the NF-B and MAPK pathways mediate the 
interaction between 1-AR and IL-6 in keratinocytes. Persistently high levels of IL-6 
have been detected in autoimmune and chronic inflammatory diseases (Tanaka & 
Kishimoto, 2012) and chronic pain conditions (Sommer et al., 2018), and targeting IL-
6 has been proposed as a therapeutic treatment for these conditions (Tanaka & 
Kishimoto, 2012; Kishimoto et al., 2015). Whether 1-AR blockade suppresses IL-6 
production in these conditions requires further study.  
Stimulation of 1-AR reduced 1B-AR gene expression levels, both in naïve and 
TNF-treated keratinocytes. In cardiomyocytes, 1-AR stimulation results in 
differential regulation of 1-AR subtype expression, i.e. an increase in 1A-AR mRNA 
levels, and a down-regulation of 1B-AR and 1D-AR mRNA expression (Li et al., 
1995; Rokosh et al., 1996; Autelitano & Woodcock, 1998). In addition, in rabbit aortic 
smooth muscles cells, stimulation of 1-AR transiently reduced 1-AR mRNA levels 
at 4 h and the expression level gradually returned to basal levels over 24 h (Izzo et 
al., 1990). This downregulation of 1B-AR expression following 1-AR stimulation was 
mediated through an inhibition on 1-AR gene transcription and a reduction in 1-AR 
mRNA stability (Izzo et al., 1990; Rokosh et al., 1996). For unknown reasons, pre-
treatment of 1-AR antagonist prazosin did not block the effects of 1-AR stimulation 
on 1-AR downregulation in keratinocytes in the present study. Thus, further 
investigation is warranted. 
ARs have been suggested to play an important role in regulation of normal 
inflammatory processes (Scanzano & Cosentino, 2015). However, dysregulation of 
ARs during inflammation may amplify inflammatory responses and transform the 
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acute pathological process of the disease or condition into a chronic state (Scanzano 
& Cosentino, 2015). For example, stimulation of 1-AR during chronic stress in human 
testicular peritubular cells elevates production of inflammatory cytokines such as IL-
6 and monocyte chemoattractant protein-1 (MCP-1); this inflammatory state is 
associated with male infertility (Rossi et al., 2018). In a chemically-induced 
hepatocellular carcinoma rat model, sympathetic nerve fibre innervation increased in 
the liver, accompanied by high levels of inflammatory cytokines IL-6, TGF-, and 
MCP-1 (Huan et al., 2017). Activation of 1-AR in Kupffer cells (macrophage-like 
inflammatory cells in the liver) induced the production of inflammatory cytokines, 
thereby contributing to hepatocarcinogenesis (Huan et al., 2017). In chronic pain 
conditions, such as complex regional pain syndrome (CRPS), increased levels of 
inflammatory cytokines and 1-AR were detected in skin isolated from the 
symptomatic (affected) limb of CRPS patients and in animal models of CRPS (Birklein 
et al., 2014; Drummond et al., 2014b; Drummond et al., 2014a; Drummond et al., 
2014c; Finch et al., 2014; Drummond et al., 2018). Moreover, stimulation of 1-AR 
provoked pain and hyperalgesia in a subgroup of patients with CRPS (Drummond et 
al., 2018), whereas administration of the 1-AR inverse agonist prazosin alleviated 
mechanical allodynia in patients (Drummond et al., 2016) and unweighting of the 
affected limb in a fracture model of CRPS (Drummond et al., 2014b). Our current 
study suggests that 1-AR may influence inflammatory cytokine production in the skin 
in a positive feedback loop. Inflammatory cytokines produced by local tissue in the 
skin directly bind to their receptors on peripheral nociceptive neurons and increase 
nociceptive neuron sensitization (Ji et al., 2014; Obreja et al., 2018). This may be an 
important source of pain in conditions such as CRPS. 
In the tightly-controlled in vitro cell culture model used in this study, a reciprocal 
interaction between 1-AR and inflammatory cytokines in keratinocytes resulted in a 
synergistic increase in IL-6 levels. In addition, stimulation of 1-AR reduced NGF 
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production. These findings are intriguing; nonetheless, it is important to establish 
whether the interaction between inflammatory cytokines and 1-AR plays a role in 
amplifying normal inflammatory processes, and whether chronic exposure 
(weeks/months/years) to TNF, as in some disease states, results in chronic 
upregulation of 1-AR and IL-6 production. In particular, if left unchecked, the 
interaction could augment chronic inflammatory diseases, chronic pain, and stress-
induced cancer progression (Heijnen et al., 1996; Perez et al., 2009; Li et al., 2013; 
Birklein et al., 2014; Huan et al., 2017; Rossi et al., 2018). If so, targeting this 
interaction may help to prevent progression of diseases into a chronic stage. 
Conversely, as stimulation of 1-AR reduced NGF production in our cell culture model, 
1-AR blockade might prevent diminution of NGF levels in keratinocytes after injury 
and support normal regeneration of peripheral nerves. An in vivo approach will be 
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Chapter 4. Alpha1-adrenoceptor stimulation induces 
interleukin-6 production in UVB-induced skin 
inflammation 
4.1. Preface 
This following chapter is written as a manuscript for submission to a peer-reviewed 
journal.  
 
Chapter 2 and Chapter 3 identify a positive feedback interaction between 1-AR and 
inflammatory mediators in keratinocytes, in vitro, which may play an important role in 
cutaneous inflammation.  In Chapter 4, using UVB-induced skin inflammation as an 
experimental model, the positive feedback interaction between 1-AR and 
inflammatory mediator is further assessed to determine whether the interaction seen 
in vitro is also present in vivo 
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4.2. Abstract 
The alpha1-adrenoceptor (1-AR) may play a role in cutaneous inflammation. 1-AR 
interact in a vicious cycle with inflammatory mediators in cultured keratinocytes. In 
this study, the role of 1-AR in cutaneous inflammation was further elucidated in vivo, 
utilizing a skin microdialysis technique. UVB irradiation to the skin was used to induce 
skin inflammation in 11 healthy participants. Phenylephrine, an 1-AR agonist, was 
perfused through microdialysis fibres that were inserted both in UVB-exposed skin 
and the contralateral normal skin. Saline was perfused through separate fibres, in 
parallel with the phenylephrine fibres, as an experimental control. UVB irradiation 
induced skin inflammation, marked by histological changes in the skin. This was 
enhanced by 1-AR stimulation post-UVB exposure, as evidenced by cutaneous IL-6 
production. These results suggest that 1-AR signalling enhances cutaneous 
inflammatory responses post-injury, and that maintaining a homeostatic interaction 
between 1-AR and inflammatory mediators may be important in preventing the 
development of a persistent inflammatory state in the skin.    
 
4.3. Introduction 
The alpha1-adrenoceptor (1-AR) is a transmembrane receptor and a target of 
sympathetic catecholamine neurotransmitters, such as adrenaline and noradrenaline. 
The 1-AR is expressed primarily in smooth muscle cells where it regulates smooth 
muscle contraction. However, recent studies have shown that 1-AR is also 
expressed in other types of cells, such as immune cells (Heijnen et al., 1996; Ricci et 
al., 1999), and keratinocytes (Dawson et al., 2011; Li et al., 2013; Wijaya et al., 2020b). 
This has prompted investigations into novel physiological roles of 1-AR. Particularly, 
in the past few decades, growing evidence indicates important roles of 1-AR in 
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modulating inflammatory responses in immune cells and resident cells, such as 
keratinocytes in the skin. 
Resident cells at the site of injury release inflammatory mediators (cytokines and 
growth factors) to provide protection, fight infection and assist with repair. We recently 
reported that tumour necrosis factor  (TNF), a pro-inflammatory cytokine, induced 
1-AR expression in a human immortalized keratinocyte cell line (Wijaya et al., 2020b), 
and that further stimulation of 1-AR heightened the production of interleukin (IL)-6 in 
these cells (Wijaya et al., 2020a). These findings imply a vicious cycle between 1-
AR and IL-6 in keratinocytes.  
In this study, the role of 1-AR in modulating the inflammatory response in inflamed 
skin of healthy people was further investigated, in vivo, utilizing local UVB irradiation 
to induce inflammation in the skin. Stimulation of 1-AR in non-inflamed and inflamed 
skin was performed by perfusing the 1-AR agonist phenylephrine through 
microdialysis fibres. Saline solution was perfused simultaneously through separate 
microdialysis fibres, in parallel with the phenylephrine, as an experimental control. It 
was hypothesized that 1-AR stimulation in inflamed skin would trigger more IL-6 
production, compared to saline in inflamed skin or phenylephrine and saline in non-
inflamed skin of healthy people. 
 
4.4. Material and methods 
This study was an exploratory study to follow-up the previous in vitro studies 
investigating the role of 1-AR in cutaneous inflammation (Wijaya et al., 2020b, 2020a) 
and to confirm whether previous in vitro observation was also present in vivo. This 
study was not registered as a clinical trial. The primary outcome of the study was to 
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investigate whether 1-AR stimulation can increase IL-6 production in inflamed skin. 
As the study was exploratory, no study power analysis was calculated.      
 
4.4.1. Participants 
The study group consisted of 11 men aged between 18 and 50 years (mean age ± 
SD 24.7 ± 8.7 years) in good health. Due to the time limitation of the study, only a few 
participants were available for recruitment. None of the participants had a medical 
condition that affected their heart, blood vessels, skin, liver or kidneys that required 
regular treatment with medication, had a known sensitivity to adrenergic drugs or had 
severe hypertension, arrhythmias, hyperthyroidism or hyperglycaemia. Each 
participant provided written informed consent for the procedures, which were 
approved by the human research ethics committee at Murdoch University. 
 
4.4.2. Microdialysis and UVB exposures  
Microdialysis: After cooling the skin with ice, two microdialysis fibres (internal 
diameter 200 µm) were inserted intradermally for 15 mm into the volar aspect of the 
forearm about 1 cm apart, and another two microdialysis fibres were inserted several 
cm distally in the same forearm. The fibres consisted of a semi-permeable membrane 
with an upper cut-off of 3000 kDa. Saline (0.9%) was perfused at 4 µL/min through 
the fibres for 60 minutes, and then one pair of fibres was flushed with 5 x 10-6 M 
phenylephrine (Leis et al., 2004). Over the next 60 minutes, 5 x 10-6 M phenylephrine 
was perfused through this pair of fibres and saline was perfused through the second 
pair of fibres. The dialysate was collected on ice and then stored at -80oC. 
UVB exposure: To determine optimal settings for UV exposure, ten 1-cm diameter 
spots on the volar aspect of the left or right forearm near the wrist were exposed to 
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graded intensities of UVB radiation (Durham Erythema Tester Device; Hybec, UK). A 
mask was placed over the UVB lamp such that filtering at the ten spots ranged from 
zero to 84%. To minimize unnecessary exposure to UVB, the duration of exposure 
was adjusted for skin pigmentation in line with calibration charts provided with the 
lamp (longer exposure for more darkly pigmented skin). Twenty-four hours later, the 
skin was examined to identify the minimum dose of UVB that had evoked slight 
reddening (erythema). Subsequently, two 2 x 3 cm sites on the volar aspect of the 
contralateral forearm, separated by 1 cm, were exposed simultaneously to UVB 
radiation at twice the minimum erythema dose.  
Microdialysis after UVB exposure: Microdialysis was repeated 48 h after sites on the 
volar forearm had been exposed to UVB radiation. One of the exposed sites was 
perfused with phenylephrine and the other with saline for 60 minutes. The dialysate 
was collected, as described above. 
 
4.4.3. Skin biopsies  
Two 3-mm diameter punch biopsies were collected from each patient under local 
anaesthesia: one from a site that had been exposed to UVB radiation but 1-2 cm 
away from the microdialysis fibres, and the other from a mirror image site on the 
contralateral forearm. Biopsies were fixed in Zamboni’s solution (5% formalin, 1% 
picric acid, 0.9% saline), embedded in paraffin and cut at 10 µm for histochemical 
staining. 
 
4.4.4. Magnetic based enzyme-linked immunosorbent assay  
The dialysates collected from microdialysis fibres were used to measure IL-6 protein 
levels using a magnetic-bead based enzyme-linked immunosorbent assay (ELISA) 
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technology. The IL-6 assay kit was part of the MILLIPLEX MAP Human Adipocyte 
panel (Merck, Darmstadt, Germany). The assay was performed according to the 
manufacturer’s protocol using undiluted dialysates. The assay signal was measured 
with a Bio-Plex® 200 System and analysed using Bio-Plex Manager software (Bio-
Rad Laboratories, CA, USA). 
 
4.4.5. Histochemical staining and UVB damage score  
Prior to staining, tissue sections were de-paraffinized in xylene and rehydrated in a 
descending series of ethanol. A standard laboratory hematoxylin and eosin staining 
(H & E) protocol was applied to each section and used to determine the extent of UVB 
damage for each individual. For control and UVB irradiated skin, one image per 
section was taken with an Olympus BX51 light microscope at x20 magnification. The 
histological changes in the skin after UVB exposure were observed and four different 
parameters were used to determine the extent of UVB damage, with the operator 
blinded to the experimental group (Bissett et al., 1987; Soter, 1990). These 
parameters included: 1) an increase in epidermal thickness, 2) presence of necrotic 
cells in the epidermis, 3) dysplasia of epidermis; and 4) an increase in number of 
cellular infiltrates in the dermis. To measure epidermal thickness, namely the distance 
between the basal keratinocytes and the outer most epidermal layer, five different 
locations across the section were measured using Image J software (version 1.50d, 
National Institutes of Health, USA). These measures were averaged and the percent 
change in epidermal thickness from UVB irradiation compared to the control was 
calculated. An increase in epidermal thickness of > 10% was given a score of 1. Each 
of the other parameters were scored 0 or 1, to give a total score of 4 for UVB damage.   
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4.4.6. Statistical approach  
Since the data for IL-6 protein levels showed a highly skewed distribution, a natural 
logarithm transformation was performed prior to statistical analysis. The changes in 
IL-6 protein levels after 1-AR stimulation in normal or UVB treated skin were 
investigated in a Site (UVB, control) x Drug (phenylephrine, saline) repeated 
measures analysis of variance. The statistical analysis was performed using SPSS® 
statistical analysis software version 24 (IBM, New York, USA). 
 
4.5. Results 
4.5.1. Histological changes in the skin post-UVB exposure 
An acute exposure of the skin to UVB changed the histological structure compared 
to the unexposed skin (control). These changes included a thickened epidermal layer, 
the presence of necrotic cells in the epidermis, dysplasia of the epidermis, and an 
increase in cellular infiltrates in the dermis (Figure 4-1). These parameters were used 
to determine the extent of UVB damage (UVB damage score) in the skin of each 
participant (Table 4-1). In all but one case, epidermal thickness was at least 10% 
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Figure 4-1. Skin histological changes post-UVB exposure 
Histological changes in the skin were compared between control and post-UVB 
exposure. The tissues were cut at 10 m thickness and stained using haematoxylin 
& eosin staining. The representative pictures were taken with a light microscope at 
x40 magnification. Ep=epidermis, Sc=stratum corneum, D=dermis, TEp=thickened 
epidermis, N=necrotic cells. The red box represents an increased number of cellular 
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(out of 4)  
1 1 0 0 0 1 
2 1 1 1 1 4 
3 1 1 1 1 4 
4 0 0 0 0 0 
5 1 1 1 0 3 
6 1 0 1 1 3 
7 1 0 0 0 1 
8 1 0 1 0 2 
9 1 0 0 1 2 
10 1 0 1 1 3 
11 1 0 1 0 2 
* 0 = absent; 1 = present 
 
 
4.5.2. IL-6 protein levels  
The protein levels of IL-6 measured in dialysates varied highly among individuals. 
Thus, to reduce the skewness of this data, IL-6 protein levels were transformed to a 
natural logarithm for statistical analysis and presented in Figure 4-2. UVB exposure 
did not change IL-6 protein levels, compared to the untreated skin (control). Moreover, 
perfusion of the 1-AR agonist phenylephrine in the control skin did not change IL-6 
protein levels measured in the dialysates (Figure 4-2 A). However, changes in IL-6 
production at phenylephrine-perfused sites after UVB treatment were greater than 
changes in IL-6 production at saline-perfused sites after the UVB treatment [Site x 
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Drug interaction F(1,10) = 5.27, p = 0.045]. This interaction remained statistically 
significant after excluding the participant with no evidence of skin damage from the 
analysis (p = 0.047). Investigation of this interaction indicated a nett increase in IL-6 
levels after UVB exposure during phenylephrine perfusion relative to saline perfusion, 
represented as the IL-6 difference score (Figure 4-2 B).  
 
 
Figure 4-2. IL-6 protein levels in dialysates 
(A) IL-6 protein levels were measured by ELISA from skin microdialysis dialysates. 
(B) Changes in IL-6 production at phenylephrine-perfused sites after UVB treatment 
in comparison to changes in IL-6 production at saline-perfused sites after the UVB 
treatment [Site x Drug interaction F(1,10) = 5.27, p = 0.045]. The IL-6 difference score 
= [phenylephrine(UVB) – phenylephrine(control)] – [saline(UVB) – saline(control)]. The graphs 
represent the mean   SEM of IL-6 protein levels that were transformed to natural 
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4.6. Discussion 
This study demonstrated that acute UVB irradiation caused an injury to the skin, 
characterized clinically by erythema (redness) and histologically by structural 
changes in the skin (Soter, 1990). The skin histological changes included an increase 
in epidermal thickness, necrotic keratinocytes, a dysplasia of the epidermis, and an 
increased number of cellular infiltrates in the dermis, such as mast cells, neutrophils 
and monocytes (Soter, 1990). However, the extent of UVB damage differed among 
participants, possibly due to differing skin types (D'Orazio et al., 2013). While signs 
of skin inflammation due to UVB exposure were observed clinically and histologically, 
we did not observe any consistent change in inflammatory cytokine IL-6 levels after 
the UVB treatment. 
A microdialysis fibre consists of semipermeable membrane that allows a passive 
diffusion between solutions inside and outside the membrane. The skin microdialysis 
technique was utilized to investigate the effect 1-AR stimulation in cutaneous 
inflammation, in vivo. Perfusion of the 1-AR agonist phenylephrine in UVB-induced 
skin inflammation enhanced cutaneous IL-6 protein production relative to changes 
after saline perfusion. Keratinocytes are the primary IL-6 producing cells in the skin 
and express 1-AR (Dawson et al., 2011; Li et al., 2013; Wijaya et al., 2020b). We 
have previously shown that 1-AR stimulation induced IL-6 production in cultured 
keratinocytes (Wijaya et al., 2020a). Other resident cells in the skin, such as resident 
immune cells, Langerhans cells and dermal fibroblasts also secrete IL-6 in smaller 
amounts (Castells-Rodellas et al., 1992; Feghali et al., 1992; Wang et al., 2004) and 
express 1-AR (Maestroni, 2000; Sterin-Borda et al., 2007; Grisanti et al., 2011a; 
Grisanti et al., 2011b; Liao et al., 2014). Grisanti and colleagues showed that 
stimulation of 1-AR in peripheral immune cells heightened lipopolysaccharide-
induced cytokine production (Grisanti et al., 2011b). However, whether other resident 
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skin cells contributed to this 1-AR-induced IL-6 production in dialysates in the current 
study requires further investigation. 
IL-6 is a pleiotropic cytokine which plays an important role in normal skin inflammatory 
responses. However, persistently high levels of cutaneous IL-6 have been found in 
several chronic pain conditions (Huygen et al., 2002; Birklein et al., 2014) and chronic 
inflammatory skin diseases (Goodman et al., 2009; Tanaka et al., 2014). UVB 
irradiation is a common type of skin injury and prolonged UVB exposure is associated 
with heightened risk of developing melanoma. Melanocytes and melanomas produce 
IL-6 (Krüger-Krasagakes et al., 1995), and persistent high levels of IL-6 may play an 
important role in cancer progression (reviewed by (Hoejberg et al., 2012)). Thus, a 
vicious cycle between 1-AR and IL-6 in the skin, following prolonged UVB exposure, 
if unchecked, might contribute to melanoma malignancy progression.  
We acknowledge that a larger or more homogenous sample than that used in this 
study might be needed to detect significant change in IL-6 levels after UVB exposure. 
In addition, an alternative technique to induce cutaneous inflammation that is 
independent from skin type, such as tape stripping (Holzmann et al., 2004), might 
induce inflammation more consistently than UVB exposure. Further studies involving 
additional participants and a stronger model of cutaneous inflammation could provide 
a clearer insight into the role of 1-AR in cutaneous inflammation and its interaction 
with inflammatory mediators, in vivo. 
Nevertheless, the present findings suggest that activation of 1-AR following in an 
injury to the skin, enhances cutaneous inflammation, reflected by increased levels of 
IL-6 in dialysates. While a positive feedback interaction between 1-AR and IL-6 in 
the skin may be important for normal inflammatory responses, dysregulation of this 
interaction could play a key role in the development of chronic cutaneous 
inflammation and associated skin disease. 
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Chapter 5. Inflammation and complex regional pain 
syndrome: The role of alpha1-adrenoceptors 
5.1. Preface 
This following chapter is written as a manuscript for submission to a peer-reviewed 
journal.  
 
The role of 1-AR in cutaneous inflammation in normal conditions, in vitro  and in vivo, 
has been described in the previous three chapters. In Chapter 5, the role of 1-AR  in 
skin inflammation is further elucidated in primary keratinocytes obtained from healthy 
controls and  CRPS patients, as ex vivo pathological models, to determine the role of 
1-AR in inflammation under pathological conditions.   
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5.2. Abstract 
Previous studies have shown that alpha1-adrenoceptors (1-AR) and inflammatory 
mediators (inflammatory cytokines and growth factors) may play important roles in 
the development and maintenance of persistent inflammation and pain in a subset of 
patients with complex regional pain syndrome (CRPS). In particular, we have shown 
that 1-AR and inflammatory mediators interacted in a vicious cycle to promote 
inflammatory mediator production in an immortalized keratinocyte cell line. In this 
study, this vicious cycle was further investigated in primary keratinocytes obtained 
from healthy control volunteers and from CRPS patients. It was hypothesized that the 
vicious cycle between 1-AR and inflammatory mediators would be stronger in CRPS 
compared to control primary keratinocytes. A pro-inflammatory cytokine, tumour 
necrosis factor alpha (TNF) was administered to cultured primary keratinocytes for 
24 hours to provide an environment resembling skin inflammation. Following this 
treatment, the 1-AR agonist phenylephrine (PE) was added and incubated for 6 
hours. Cells treated with media, TNF, or PE without TNF were used as 
experimental controls. Exposure to TNF induced inflammatory cytokine mRNA and 
protein levels and reduced NGF mRNA levels in primary keratinocytes. Additional 
stimulation of 1-AR using PE resulted in a heightened production of IL-6 mRNA and 
protein, and a further reduction in NGF mRNA levels. In CRPS keratinocytes, 
baseline 1-AR protein expression was strongly associated with IL-6 mRNA 
production after 1-AR stimulation with PE. These findings suggest that a positive 
feedback interaction between 1-AR and inflammatory mediators in CRPS 
keratinocytes contributes to the development of persistent inflammation in this 
syndrome. Hence, targeting this interaction at an early stage of CRPS may be a useful 
therapeutic target to prevent the progression of the condition into the chronic stage.  
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5.3. Introduction 
Sympathetic nervous system (SNS) dysfunction may be involved in the development 
and maintenance of pain in a subgroup of patients with complex regional pain 
syndrome (CRPS), a type of neuropathic pain (Drummond PD, 2004; Knudsen et al., 
2019). A cutaneous injection of adrenergic ligands, noradrenaline or adrenaline, into 
the symptomatic (affected) limbs evokes greater and prolonged pain compared with 
injection into unaffected limbs (Davis et al., 1991; Ali et al., 2000), whereas 
sympathetic blockade reduces pain (Yoo et al., 2011; van Eijs et al., 2012; Harden et 
al., 2013). Our findings and those of others indicate that adrenoceptors (ARs) may 
facilitate this coupling between the SNS and nociceptors (Li et al., 2013; Drummond 
et al., 2014a; Drummond et al., 2014c; Finch et al., 2014; Drummond et al., 2016; 
Drummond et al., 2018). Our particular interest is in the alpha1-adrenoceptors (1-
AR), as their expression is heightened in the epidermis and dermal nerves bundles 
in the symptomatic limb of CRPS patients (Finch et al., 2014; Drummond et al., 2018) 
and in animal models of neuropathic pain (Drummond et al., 2014a; Drummond et al., 
2014c). Moreover, stimulation of this receptor through its agonist phenylephrine (PE) 
induces prolonged mechanical hyperalgesia (Davis et al., 1991; Drummond et al., 
2018), while 1-AR antagonist administration alleviates hyperalgesia (Davis et al., 
1991; Ali et al., 2000), mechanical allodynia (Drummond et al., 2016) and unweighting 
(Drummond et al., 2014b). 
One of the triggers of CRPS is injury to a limb, involving fracture or soft tissue injury 
(CRPS type I) or major peripheral nerve damage (CRPS type II). Inflammatory 
cytokines (e.g. tumour necrosis factor  (TNF), interleukin (IL)-1, IL-6) and growth 
factors (e.g. nerve growth factor (NGF)), are released by resident tissue, such as skin, 
to assist healing, repair and regeneration after injury. In normal conditions, 
inflammation resolves once the injury is healed. However, in CRPS patients, the 
inflammatory state persists. This exaggerated inflammatory response is associated 
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with elevated levels of inflammatory cytokines, such as TNF, IL-1, and IL-6, in the 
skin and blister fluid obtained from the affected limb (Huygen et al., 2002; Groeneweg 
et al., 2006; Heijmans-Antonissen et al., 2006; Kramer et al., 2011; Birklein et al., 
2014) and is believed to complicate the pathophysiology of CRPS. Moreover, the 
presence of inflammatory mediators and NGF induces neuropathic pain behaviours 
when injected into uninjured (Wagner & Myers, 1996a; Schafers et al., 2003; Zelenka 
et al., 2005) or injured tissue (DeLeo et al., 1996; Schafers et al., 2003; Kim & 
Moalem-Taylor, 2011). However, the mechanisms that underlie this persistent 
inflammatory condition in CRPS are not fully understood. 
Growing evidence suggests that 1-AR signalling modulates inflammatory responses 
in several types of cells, such as immune cells (Rouppe van der Voort et al., 2000; 
Grisanti et al., 2011b), Kupffer cells (macrophage-like inflammatory cells in liver) 
(Huan et al., 2017), and human testicular peritubular cells (Rossi et al., 2018). We 
recently reported that an inflammatory cytokine, TNF, induced 1-AR subtype B 
(1B-AR) expression in an immortalized human keratinocyte cell line (HaCaT cells; 
(Wijaya et al., 2020b)) and that further stimulation of this activated 1-AR enhanced 
the production of the inflammatory cytokine IL-6 from these cells (Wijaya et al., 2020a), 
suggesting a positive feedback loop between 1-AR and inflammatory cytokines in 
keratinocytes. 
In the current study, we further investigated the positive feedback interaction between 
1-AR and inflammatory cytokines in keratinocytes obtained from the skin of CRPS 
patients and healthy control volunteers (primary keratinocytes). Following activation 
of these cells with the pro-inflammatory cytokine TNF, the 1-AR agonist PE was 
administered to determine whether stimulation of this receptor would generate 
heightened production of pro-inflammatory cytokines. It was hypothesized that 1-AR 
would interact in a vicious cycle with inflammatory cytokines in cultured keratinocytes 
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ex vivo and that this interaction would be stronger in keratinocytes that originated 
from CRPS patients than healthy controls. 
 
5.4. Material and methods 
This study was an exploratory study to investigate the positive feedback interaction 
between 1-AR and inflammatory cytokines in keratinocytes obtained from the skin of 
CRPS patients and healthy control volunteers. Due to time limitations and patient 
availability, no study power analysis was calculated. 
 
5.4.1. Participants 
This study was approved by the human ethics committee of Murdoch University. Nine 
CRPS patients, who met the Budapest diagnostic criteria for CRPS (Harden & Bruehl, 
2005; Harden et al., 2010b), were recruited from a local pain clinic. Both patients and 
healthy volunteers gave their informed consent at the beginning of the study.  
On the morning of the visit, patients were requested not to take analgesic medication, 
but took other scheduled medications as usual. Patients underwent a short clinical 
interview and sensory tests. The sensory tests were performed to both affected 
(ipsilateral) and unaffected (contralateral) limbs in a temperature-controlled room 
between 21 and 24oC. The tests included assessment to pressure-pain threshold, 
pinprick sharpness, von Frey filament touch sensitivity to a single or 5 applications, 
and mechanical allodynia to skin brushing (light touch response). Pressure-pain 
threshold was measured using an algometer (FDX; Wagner Instruments, Greenwich, 
CT, USA) with a modified 8-mm diameter hemispheric rubber tip that was applied 
once at each site at 100 g/second until the participant reported pain. A spring-loaded 
metal pin at a force of 40 g (NeuroPen; Owen Mumford, Woodstock, Oxfordshire, 
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United Kingdom) was applied for 2 seconds and a rating of sharpness was recorded. 
A von Frey nylon monofilament with a bending force of 10 g (NeuroPen; Owen 
Mumford, Woodstock, Oxfordshire, United Kingdom) was applied once and then five 
times at 1-second intervals. The sharpness of these applications was rated at the end 
of the application series. In addition, skin temperature was measured on the dorsal 
surface of the base of each digit on the affected and unaffected limbs using an 
infrared thermometer. The temperature difference between affected and unaffected 
limbs was determined by taking the average of temperature of digits on each limb. 
For the control group, eight age-matched healthy volunteers, without any acute or 
chronic pain or inflammation, were also recruited.  
 
5.4.2. Isolation and culture of primary keratinocytes from skin biopsies 
A 3-mm diameter punch skin biopsy was collected from the affected limb of CRPS 
patients or at a similar site in healthy control volunteers, under local anaesthesia. The 
skin biopsies were washed in cold PBS (no Mg2+/Ca2+) containing 100 U/mL penicillin 
and 100 g/mL streptomycin. All the materials used in the isolation and maintenance 
of primary keratinocyte culture were obtained from GibcoTM (Thermo Fisher Scientific, 
MA, USA) unless otherwise stated. The isolation and dissociation of primary 
keratinocytes from the skin biopsy were performed using protocols published 
previously with some modifications (Aasen & Izpisua Belmonte, 2010). Briefly, a skin 
biopsy was incubated in a digestive enzyme solution, containing 1.3 U/mL dispase, 1 
g/mL fungizone (Amphotericin B) and 200 g/mL kanamycin in keratinocyte media 
(KM; EpiGRO™ Human Epidermal Keratinocyte Complete Culture Media Kit, Merck, 
Germany), for 12-16 h, at 4oC to separate the epidermal layer. After several washes 
in KM to remove dispase, the epidermis was slowly separated from the dermis using 
tweezers and incubated in trypsin solution (1X TrypLE™ Express Enzyme) in a sterile 
culture dish, with the basal layer of epidermis facing down, for 20-30 min at room 
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temperature. Primary keratinocytes were gently dissociated from the epidermis by 
gently rubbing the epidermis against the base of the dish. The cells were collected 
and centrifuged for 5 min at 200 G at room temperature. The cell pellet was 
resuspended gently in KM media and seeded in a 10-mm cell culture dish. The media 
was changed after 4 days, and every 2 days thereafter. The cultivation and 
maintenance of the keratinocytes were performed in a controlled incubator at 37oC 
and 5% CO2. 
 
5.4.3. Experimental procedure  
The second or third passage of CRPS and healthy keratinocytes was plated in 24-
well plates. To abolish the effect of epinephrine (neurotransmitter ligand for 1-AR) in 
the media supplement, primary keratinocytes were incubated in non-supplemented 
KM (nsKM) for 24 h. Human recombinant TNF (Peprotech, New Jersey, USA) was 
diluted in nsKM at a final concentration of 10 ng/mL and was administered to the cells 
for 24 h. This concentration has been shown previously to induce inflammatory 
cytokines, nerve growth factor (NGF), and 1-AR subtype B (1B-AR) expression in a 
human keratinocyte cell line, HaCaT cells (Wijaya et al., 2020b). The 1-AR selective 
agonist, phenylephrine (PE), was then added to the cells at a final concentration of 1 
M or 10 M and the cells were incubated for another 6 h. Cells treated with nsKM, 
PE, or TNF only were used as experimental controls. Each treatment was performed 
in 4 wells (4 technical replicates). At the end of the incubation period, the conditioned 
media was collected to measure inflammatory cytokine and NGF protein levels. In 
addition, the cells were lysed with lysis buffer and technical replicates were pooled 
prior to isolation of total RNA.   
 
Chapter 5. Inflammation and CRPS: The role of 1-adrenoceptors  
 83 
5.4.4. Quantitative real-time PCR  
Total RNA was isolated and purified from the cell lysates using an Isolate II RNA mini 
kit (Bioline, NSW, Australia). The amount of RNA extracted from the cells was 
quantified using a NanoDrop 2000c UV-Vis Spectrophotometer (Thermo Scientific, 
DE, USA). One g total RNA was converted to cDNA using a Sensifast™ cDNA 
synthesis kit (Bioline, NSW, Australia), according to the manufacturer’s protocol. A 
SYBR® Green-based quantitative real-time PCR (qRT-PCR) assay, followed by 
melting curve analysis, was used to measure gene expression levels of 1-AR 
subtype B (1B-AR) and inflammatory cytokines IL-1, IL-6, IL-8, and NGF, while a 
hydrolysis probe-based qRT-PCR assay was used to measure levels of 1-AR 
subtype A (1A-AR) and D (1D-AR). The primer sets used in qRT-PCR are listed in 
Table 5-1 and Table 5-2, for SYBR® Green-based and hydrolysis probe-based assays, 
respectively. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an 
endogenous control in both assays. All of the primers were validated to amplify only 
mRNA and not genomic DNA (unpublished data). The qRT-PCR assay was 
performed using a ViiA™ 7 Real-Time PCR System (Applied Biosystems™, MA, 
USA). A cycle threshold (Ct) value of each sample was collected at the end of the 
qRT-PCR run (40 cycles). The change in gene expression as a result of treatments 
compared to the untreated cells (naïve) was represented by Ct as described 
previously (Yuan et al., 2006). The mean ± SEM of the gene expression change in 





Chapter 5. Inflammation and CRPS: The role of 1-adrenoceptors  
 84 
Table 5-1. Primer sets used in a SYBR® Green qRT-PCR assay  
 
 








5.4.5. Multiplex enzyme-linked immunosorbent assay  
Conditioned media collected from each treatment was used to measure inflammatory 
cytokine and NGF protein levels from primary keratinocytes. The protein levels were 
measured using a magnetic-bead based multiplex enzyme-linked immunosorbent 
assay (ELISA) technology that allows simultaneous measurement of different 






‘5 – 3’ 
Reverse Sequence 





NM_000584 ATG ACT TCC AAG CTG GCC GT TCC TTG GCA AAA CTG CAC CT 82 
IL6 
(IL-6) 
NM_000600 AGC CCT GAG AAA GGA GAC ATG ACC AGG CAA GTC TCC TCA TTG 144 
IL1B 
(IL-1) 
NM_000576 CTG TCC TGC GTG TTG AAA GA TTG GGT AAT TTT TGG GAT CTA CA 70 
NGF 
(NGF) 
NM_002506 TGT GAT CAG AGT GTA GAA CAA CA CGG ACC CAA TAA CAG TTT TAC C 97 
GAPDH NM_002046 GGG TGT GAA CCA TGA GAA GAC TGT GGT CAT GAG TCC T 136 
ADRA1B 
(1B-AR) 








ADRA1A (1A-AR) NM_000680 Hs00169124_m1 112 
ADRA1D (1D-AR) NM_000678 Hs00169865_m1 68 
GAPDH NM_001256799 Hs02758991_g1 93 
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previously shown to be elevated in chronic neuropathic pain conditions and CRPS 
(Heijmans-Antonissen et al., 2006; Uceyler et al., 2010; Kramer et al., 2011; Birklein 
et al., 2014) were chosen from the MILLIPLEX MAP Human Adipocyte panel (Merck, 
Darmstadt, Germany). The assay was performed according to the manufacturer’s 
protocol using undiluted media. The assay signal was measured with a Bio-Plex® 200 
System and analysed using Bio-Plex Manager software (Bio-Rad Laboratories, CA, 
USA). 
 
5.4.6. Western blotting  
The materials used for the western blotting (WB) method were acquired from Thermo 
Fisher Scientific (MA, USA), unless stated separately. The WB technique was used 
to determine baseline 1-AR protein expression levels in CRPS and healthy control 
keratinocytes. Keratinocytes from each participant were lysed using NP40 lysis buffer 
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Nonidet-P40 or Triton X-100) supplemented 
with cOmplete™ protease inhibitor cocktail (Roche, via Merck, Darmstadt, Germany; 
1 tablet / 10 ml NP40 lysis buffer). The lysates were incubated on ice for 30 min with 
application of vigorous vortexing every 10 min. At the end of the incubation period, 
the lysates were centrifuged at 12,000 G for 15 min at 4oC. The supernatants were 
collected and total protein concentration was determined using a Pierce™ BCA 
protein assay kit. Twenty-five g total protein was prepared in NuPAGE™ LDS 
Sample Buffer with reducing agent, boiled at 95oC for 10 min, and loaded into 
NuPage™ 4-12% Bis-Tris gels. Gel electrophoresis was performed in 1X NuPAGE™ 
MES SDS running buffer at 90 volts (constant), for 2.5 h. The protein was transferred 
onto a 0.45 m nitrocellulose membrane using a wet-transferred system (Mini Trans-
Blot® Cell, Bio-Rad Laboratories, CA, USA) in 1X transfer buffer (192 mM glycine, 25 
mM Tris) with 20% (v/v) methanol, at 100 volts for 1.5 h. Immunoblotting steps were 
performed at room temperature (unless stated separately) and with gentle rocking. 
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Following several washes in tris-buffered saline pH 7.4 (TBS; 10 mM Tris, 150 mM 
NaCl) to remove excess methanol, membranes were incubated in 5% skimmed milk 
in TBS buffer for 1 h. Primary antibodies against 1-AR or GAPDH (as a loading 
control) were diluted in TBS, supplemented with 0.05% Tween-20 (TBS-T; Sigma-
Aldrich, St. Louis, MO) and 0.5% skimmed milk. The incubation of primary antibody 
was performed overnight at 4oC. The next day, membranes were washed with TBS-
T (3 x 15 min) prior to secondary antibody incubation in TBS-T with 0.5% skimmed 
milk for 1 h. Primary and secondary antibodies are listed in Table 5-3. After three 
subsequent washes with TBS-T (15 min each), enhanced chemiluminescence 
substrate solution (Clarity™, Bio-Rad Laboratories, CA, USA) was added and the 
chemiluminescence signals were captured using ChemiDoc MP (Bio-Rad 
Laboratories, CA, USA). The protein expression levels of 1-AR and GAPDH were 
determined through measurement of band signal (in optical density – OD) at 55 kDa 
and 37 kDa, respectively, using Image™ Lab analysis software (Bio-Rad Laboratories, 
CA, USA). As the protein size of 1-AR and GAPDH are similar, the detection of 
GAPDH was performed following WB for 1-AR, using WB membrane stripping 
protocol: membranes were washed in TBS-T (3 x 15 min), incubated with Restore™ 
WB stripping buffer for 15 min, washed in TBS-T (3 x 15 min) and rinsed in TBS. WB 
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Table 5-3. Primary and secondary antibodies 
 
 
5.4.7. Statistical approach 
Multiple comparison analysis, utilizing a general linear model with repeated measures, 
was performed to determine mean differences between: (1) treatment conditions and; 
(2) CRPS and healthy control groups. The change in gene expression levels caused 
by treatments (in Ct) and the values generated from multiplex ELISA assays were 
investigated in the statistical analyses. The mean values of baseline 1-AR protein 
expression (in OD) of CRPS and healthy control keratinocytes were analysed using 
an independent-samples Student’s t-test to determine the mean difference between 
groups. A Pearson’s correlation analysis was performed to investigate the association 
between baseline 1-AR protein expression and inflammatory cytokine and NGF 
levels. All statistical analyses were performed using SPSS® statistical analysis 
software version 24 (IBM, New York, USA). 
 






















GE Healthcare, Freiburg, Germany 
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5.5. Results 
5.5.1. Demographic characteristics of participants 
Nine CRPS patients and eight healthy control volunteers participated in this study. 
There was no age difference between CRPS patients (51.1 ± 11.9 years; Mean ± SD) 
and healthy control volunteers (49.9 ± 10.7 years). The percentage of female 
participants was 44% and 50% in the CRPS and healthy control groups respectively. 
Eight of the patients had chronic CRPS (duration more than 36 months) when the 
skin biopsies were obtained, and the other patient had CRPS for 23 months. Other 
demographic characteristics are summarised in Table 5-4 and Table 5-5.  
 












 CRPS Control 
Age ± SD (years) 51.1 ± 11.9  49.9 ± 110.7 
Female 44% 50% 
Duration ± SD (months)  114 ± 83.5  
Extremity affected    
Left upper extremity 22%  
Right upper extremity 22%  
Left lower extremity 11%  
Right lower extremity 44%  
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The results of individual quantitative sensory tests from CRPS patients are presented 
in Table 5-6. Significant differences in pressure pain threshold, pinprick hyperalgesia 
and touch sensitivity measured by a single or multiple application of von Frey hair 
were shown between affected and unaffected limbs. Different responses to light touch 
were observed between patients, while there was no consistent difference in 
temperature between affected and unaffected limbs. In Patients 1 and 4 pain had 
spread globally and to the contralateral limb, respectively. The skin biopsy was taken 

















Chapter 5. Inflammation and CRPS: The role of 1-adrenoceptors  
 90 




Affected Contralateral Affected Contralateral Affected Contralateral Affected Contralateral Affected Contralateral Affected Contralateral
1 43 M 0.245 1.475 9 5 9 3 10 4 Painful Normal 26.18 26.44




3 54 F 0.705 1.355 6 2 6 0 8 1 Normal Tickling 33.08 32.54
    4 




5 53 M 0.965 1.720 6 1 2 1 3 1 Normal Normal 34.60 31.54








8 41 M 0.945 1.630 5.5 1 2 1 2 1 Firmer Normal 23.50 24.80
9 59 F 0.460 0.740 9 7 9 8 9 8 Cold and coarse Tickling 33.32 32.62
0.553 ± 0.247 1.696 ±  1.313 5.4 ± 2.1 2.8 ±  2.6 4.9 ± 2.8 2.1 ± 2.5 6.1 ± 2.7 2.0 ± 2.5 29.47 ± 4.21 29.09 ± 3.47
Pain rating scale is from 0 (not at all painful) to 10 (the most unbearable pain ever experienced)
a) The pain had intensified in the contralateral limb. The skin biopsy was obtained from contralateral site that was more problematic (inflammed and painful) on the visit day. 
Mean ± S.D.
Pain rating to Pinprick                         
(t=6.973; p=0.000*) 
Pain rating to von Frey filaments (1X) 
(t=3.545; p=0.008*)
Pain rating to von Frey filaments (5X) 
(t=5.117; p=0.001*)
Brush (light touch responses)
Temperature (
o




Pressure Pain Threshold (kg)                 
(t=-2.599; p=0.0320*)
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5.5.2. Baseline 1-AR protein levels in healthy control and CRPS patient 
primary keratinocytes 
Baseline 1-AR protein levels in healthy control and CRPS keratinocytes were 
determined using western blotting (WB). The individual 1-AR protein levels, along 
with its GAPDH loading control, are presented in Figure 5-1. Individual variation in 1-
AR protein levels was greater in the CRPS group than in the control group.  
 
 
Figure 5-1. Baseline 1-AR protein levels in control and CRPS keratinocytes 
Baseline protein levels of 1-AR were measured in cultured keratinocytes using 
western blotting. Detection of 1-AR and GAPDH (a loading control) proteins was 
performed by western blot using antibodies listed in Table 5-3. The 1-AR and 
GAPDH protein levels are depicted as bands at 55 kDa and 37 kDa, respectively (A). 
The individual band intensity for each participant was measured, normalized to its 
GAPDH expression, and presented in the graph (B). The bars represent the Mean ± 
SEM of each group. M=Marker of protein weight in kilo Dalton (kDa); OD=optical 
density; nCRPS=9 and nControl=8; numbers 1-8 and 1-9 match healthy control and CRPS 
patient numbers as listed in Table 5-5 and Table 5-6, respectively. 
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5.5.3. The effects of TNF and/or phenylephrine treatments on inflammatory 
cytokine and NGF levels 
There were no differences in inflammatory cytokine or NGF mRNA and protein levels 
between CRPS and healthy control groups; thus, the data from both groups were 
combined and analysed together to determine the effects of TNF and phenylephrine 
treatments on inflammatory cytokine and NGF levels. TNF treatment significantly 
increased both inflammatory cytokine mRNA expression (Figure 5-2 A-C) and protein 
levels (Figure 5-2 E-G) compared to the untreated cells (naïve). In contrast, TNF 
significantly reduced NGF mRNA levels (Figure 5-2 D), while there was no change in 
protein levels (Figure 5-2 H).  
Phenylephrine (PE) administration, at either 1 or 10 M, altered inflammatory cytokine 
and NGF levels. Administration of PE alone reduced IL-1 mRNA levels at 10 M, 
compared to naïve cells (Figure 5-2 A); however, IL-1 gene expression levels did 
not change when PE was administered to activated (TNF-treated) keratinocytes. 
Changes in IL-1 mRNA levels were not reflected at the protein level. Here, 
administration of 1 M PE reduced IL-1 levels in normal keratinocytes but did not 
alter IL-1 levels in activated keratinocytes (Figure 5-2 E). Ten M PE did not alter 
IL-1 protein levels when administered to normal or activated keratinocytes, 
compared to naïve and TNF-treated cells, respectively (Figure 5-2 E). 
Phenylephrine-mediated stimulation of 1-AR significantly reduced IL-8 gene 
expression levels in normal keratinocytes and this reduction was dose dependent 
(Figure 5-2 B). However, PE administration to TNF-activated keratinocytes did not 
alter IL-8 mRNA (Figure 5-2 B) or protein (Figure 5-2 F) levels. 
Exposure to PE significantly augmented IL-6 mRNA levels (Figure 5-2 C), consistent 
with the dose-dependent increase in IL-6 protein levels (Figure 5-2 G), when PE was 
applied alone to resting keratinocytes. Stimulation of 1-AR following TNF treatment 
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resulted in an increase in IL-6 mRNA (Figure 5-2 C) and protein levels (Figure 5-2 G), 
with a dose-dependent increase at the mRNA level.   
In contrast to IL-6, administration of PE alone reduced NGF mRNA levels compared 
to naïve cells (Figure 5-2 D). Interestingly, there were further reductions in NGF 
mRNA levels when PE was administered to TNF-treated cells. However, these 
changes were not reflected at the protein level (Figure 5-2 H).   
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Figure 5-2. Inflammatory cytokine and NGF mRNA and protein levels in both 
healthy control and CRPS keratinocytes  
Healthy control and CRPS keratinocytes were administered 10 ng/ml TNF (TNF) or 
media only (naïve) for 24 h. One or 10 M phenylephrine (PE) was added to the TNF-
treated cells (TNF + PE condition) or naïve cells (PE condition) for an additional 6 h. 
At the end of the treatment, gene expression levels of inflammatory cytokines IL-1 
(A), IL-8 (B), IL-6 (C) and NGF (D) were measured using a qRT-PCR. Changes in 
gene expression as a result of treatment are represented as Ct (CtNaïve=0). 
Protein levels of inflammatory cytokine IL-1 (E), IL-8 (F), IL-6 (G) and NGF (H) 
secreted by cells into the media were measured using multiplex ELISA and are 
represented as mean ± SEM. White bars represent control keratinocytes (n=8) and 
grey bars represent CRPS keratinocytes (n=9). There were no significant differences 
either in gene expression or protein levels between control and CRPS groups. 
p<0.05 compared to naïve cells;  p<0.05 compared to all groups; *p<0.05.  
 
 
5.5.4. The effects of TNF and/or phenylephrine treatments on 1B-AR gene 
expression and NGF levels 
A preliminary experiment was performed to characterize gene expression levels of 
1-AR subtype A (1A-AR), B (1B-AR) and D (1D-AR) in primary keratinocytes. 
Consistent with 1-AR subtype expression seen in an immortalized human 
keratinocyte cell line (HaCaT cells; (Wijaya et al., 2020b)), primary keratinocytes did 
not express 1A-AR. In addition, 1D-AR mRNA levels were too low to be accurately 
measured and quantified (Ct value > 33), while 1B-AR was readily expressed 
(unpublished data). TNF exposure increased 1B-AR gene expression levels in both 
control and CRPS keratinocytes (Figure 5-3). Administration of PE to normal or 
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activated (TNF-treated) keratinocytes reduced 1B-AR mRNA levels in a dose-
dependent manner. However, there were no differences between control and CRPS 
keratinocytes in response to either treatment. 
 
 
Figure 5-3. 1B-AR gene expression levels in healthy control and CRPS 
keratinocytes  
TNF was administered to keratinocytes at 10 ng/ml for 24 h. Following TNF 
treatment, 1 or 10 M phenylephrine (PE) was added to the cells and incubated for 
another 6 h. Naïve cells treated with media only were used to estimate baseline 1-
AR expression and cells treated with PE alone were used as an experimental control. 
Changes in gene expression as a result of the treatments are represented as Ct 
(CtNaïve=0). White bars represent control keratinocytes (n=8) and grey bars 
represent CRPS keratinocytes (n=9). Data are represented as mean ± SEM. There 
were no differences between control and CRPS keratinocyte responses to either of 
the treatments. p<0.05 compared to naïve cells (at zero);  p<0.05 compared to all 
groups; *p<0.05.  
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5.5.5. Correlation analysis 
Several CRPS patients with high levels of baseline 1-AR protein produced high 
levels of IL-6 in response to 1-AR stimulation. Therefore, we were interested to 
investigate the association between the baseline 1-AR protein expression and IL-6 
production in healthy control and CRPS keratinocytes. No correlation between 1-AR 
baseline protein levels and IL-6 mRNA levels (Figure 5-4 A-C, E) was seen in the 
healthy control group apart from a positive correlation for cells treated with TNF and 
1 M PE (Figure 5-4 D). In contrast, strong positive correlations between baseline 1-
AR protein expression and IL-6 mRNA levels were observed both in normal (Figure 
5-4 F-G) and activated (TNF-treated; Figure 5-4 I-J) CRPS keratinocytes that were 
treated with phenylephrine. No correlation was observed in CRPS keratinocytes 
treated with TNF only (Figure 5-4 H).  
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Figure 5-4. Correlation analysis between baseline 1-AR protein expression and 
IL-6 mRNA levels  
Scatterplot graphs with linear regression represent the correlation between baseline 
1-AR protein levels and IL-6 gene expression changes (Ct) in response to 
treatments of: 1 M PE (A, F), 10 M PE (B, G), 10 ng/ml TNF (C, H), TNF and 1 
M PE (D, I), or TNF and 10 M PE (E, J), in healthy controls (A–E; n=8) and CRPS 




In this study, interactions between 1-AR and inflammatory mediators (cytokines and 
NGF) were investigated in primary keratinocytes obtained from CRPS patients and 
healthy control volunteers. TNF induced an inflammatory state marked by a 
significant increase in inflammatory cytokine production in primary keratinocytes and 
upregulated 1B-AR gene expression levels, while reducing NGF mRNA levels. 
Stimulation of activated (TNF-induced) 1-AR further augmented both gene 
expression and protein levels of IL-6, which suggests a positive feedback interaction 
between 1-AR and IL-6 in primary keratinocytes. In contrast to IL-6, NGF mRNA 
levels were further reduced following stimulation of 1-AR in activated keratinocytes, 
although these changes were not reflected at the protein level. While there were no 
significant differences between control and CRPS keratinocytes in responses to 
TNF and 1-AR stimulation, interestingly, 1-AR baseline protein levels correlated 
positively with the CRPS cells’ response to 1-AR stimulation in producing IL-6. These 
results suggest that whilst both CRPS and control keratinocytes behaved similarly in 
culture, inflammatory and sympathetic signalling may drive inflammatory mediator 
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production differently in vivo,  as differences in local skin inflammatory mediator levels 
were observed between CRPS patients and healthy controls (Huygen et al., 2002; 
Groeneweg et al., 2006; Heijmans-Antonissen et al., 2006; Kramer et al., 2011; 
Birklein et al., 2014).  
In the acute stage of CRPS, an excessive inflammatory response in local tissues at 
the injury site plays an important role in the development of a persistent inflammatory 
condition. Inflammatory cytokines, such as TNF and IL-6, are elevated in the 
epidermis (Birklein et al., 2014) and skin blister fluid (Huygen et al., 2002; Groeneweg 
et al., 2006; Heijmans-Antonissen et al., 2006; Kramer et al., 2011) in the affected 
limb of CRPS patients, but not in the blood (Huygen et al., 2002; Schinkel et al., 2006; 
Schinkel et al., 2009). This heightened local inflammatory response appears to be 
specific to CRPS (Kramer et al., 2011; Lenz et al., 2013). While clinical signs of 
inflammation are often reduced at the affected site in the chronic stage of CRPS, 
levels of IL-6 in skin blister fluid obtained from the affected site are higher than the 
contralateral site (Munnikes et al., 2005; Dirckx et al., 2015). In the present study, 
keratinocytes obtained from chronic CRPS patients were sensitive to 1-AR 
stimulation, and this triggered an increase in the production of IL-6 in proportion to 
basal 1-AR protein levels. While the responsiveness of CRPS keratinocytes 
obtained at the acute stage (the inflammatory phase) to 1-AR stimulation in 
producing IL-6 might be different, these results provide evidence that an abnormal 
local inflammatory response exists in some CRPS patients in the chronic stage which 
may be activated by 1-AR stimulation (e.g., during sympathetic nervous system 
arousal caused by stress).  
Signs of persistent inflammation are often detected in the affected limb of CRPS 
patients. While the mechanisms that mediate chronic inflammation are not fully 
understood, the current study suggests the contribution of a positive feedback 
interaction between 1-AR and inflammatory mediators, in particular IL-6 and NGF, 
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in the development of persistent inflammation and pain. Perez and colleagues 
showed that such cross-talk may be facilitated through the involvement of the p38 
MAPK and NF-B inflammatory signalling pathways (Perez et al., 2009). Utilizing 
mouse cardiomyocytes and 1A-AR-over-expressed rat fibroblasts, stimulation of 1-
AR resulted in a stabilization of IL-6 mRNA and a maintenance of IL-6 transcription 
factor, involving the aforementioned pathways (Perez et al., 2009). In the present 
study, stimulation of TNF-induced 1-AR further augmented IL-6 mRNA and protein 
levels, compared to cells that were treated only with phenylephrine or TNF. It is 
postulated that TNF induced IL-6 production through classical inflammatory 
signalling pathways, such as NF-B, JAK-STAT, and MAPK (Tanabe et al., 2010). 
Subsequent 1-AR stimulation might then have stabilized TNF-induced IL-6 mRNA 
and maintained transcription factors for IL-6 (Perez et al., 2009).  
Elevated IL-6 levels at the site of injury have been reported in neuropathic pain animal 
models and CRPS patients in association with neuropathic pain behaviour (DeLeo et 
al., 1996; De Jongh et al., 2003; Sabsovich et al., 2008b; Li et al., 2010; Li et al., 2013; 
Birklein et al., 2014; Guo et al., 2014; Guo et al., 2018). IL-6 evokes nociceptive 
hypersensitivity and pain when injected into normal skin (DeLeo et al., 1996; De 
Jongh et al., 2003). Additionally, systemic administration of an IL-6 receptor 
antagonist, TB-2-081, reduced neuropathic pain behaviour in a rat tibia fracture model 
of CRPS (Li et al., 2013). Studies utilizing IL-6 knockout mice showed that elimination 
of IL-6 expression reduced mechanical allodynia in a neuropathic pain mouse model 
(Ramer et al., 1998) and in a chemotherapy-induced neuropathy mouse model 
(Kiguchi et al., 2008). Together, this evidence supports the important role of IL-6 in 
nociception. Therefore, persistently high levels of IL-6 may contribute to persistent 
pain seen in CRPS patients. Importantly, IL-6 also stimulates antibody 
(immunoglobulin) production from B lymphocytes (Tanaka et al., 2014). Persistent 
and heightened production of IL-6 may trigger the development of autoimmunity and 
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autoantibody production (Tanaka et al., 2014; Kishimoto et al., 2015), and may thus 
contribute to the development of the autoimmune component in CRPS 
pathophysiology (Goebel & Blaes, 2013; David Clark et al., 2018).  
NGF is a neurotrophic factor that plays an important role in peripheral nerve survival 
and regeneration after injury. In keratinocytes, NGF acts as a chemotactic factor for 
axonal outgrowth and peripheral nerve innervation during wound healing. While TNF 
has been previously shown to induce NGF expression in an immortalized human 
keratinocyte cell line (HaCaT cells) (Takaoka et al., 2009; Wijaya et al., 2020b), we 
demonstrated that TNF reduced NGF mRNA levels in primary keratinocytes. This 
may be due to the short life span of primary keratinocytes and attenuation of cell 
growth caused by the removal of media supplement (Di Marco et al., 1991). This 
might have reduced the sensitivity of keratinocytes to TNF induction and caused 
aberrant cross-talk between TNF and NGF that decreased NGF production (Takei 
& Laskey, 2008a).  
Stimulation of 1-AR in cardiomyocytes attenuates NGF mRNA levels (Kaye et al., 
2000; Ieda et al., 2004) and this effect is reversed through pre-administration of the 
1-AR antagonist prazosin (Kaye et al., 2000). Chronic stimulation of adrenoceptors 
reduces NGF levels and results in the loss of sympathetic nerves in myocardial tissue 
(Kaye et al., 2000; Kimura et al., 2010). Consequently, this condition leads to heart 
failure. In this study, 1-AR stimulation reduced NGF mRNA levels in primary 
keratinocytes, with the greatest decreases seen in primary keratinocytes treated with 
a combination of TNF and phenylephrine. This was not reflected at the protein level, 
possibly due to the stability of NGF protein in culture (Nguyen et al., 2000) and the 
complexity of transcription-translation mechanisms (Greenbaum et al., 2003). 
Nonetheless, in vivo, attenuated skin NGF levels may hinder peripheral nerve 
regeneration and axonal outgrowth after injury and result in a reduction in cutaneous 
nerve fibre density. In patients with painful neuropathy, such as diabetic neuropathy 
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(Quattrini et al., 2008), HIV neuropathy (Obermann et al., 2008), small nerve fibre 
neuropathy (Uceyler et al., 2010), leprosy (Facer et al., 2000) and CRPS (Oaklander 
et al., 2006; Morellini et al., 2018; Rasmussen et al., 2018), a reduction in cutaneous 
nerve fibre density has been identified in skin biopsies collected from the affected 
limb, and is associated with the pain experience. 
Similar to other G-protein coupled receptors, 1-AR undergo rapid internalization to 
maintain homeostasis when the receptors are stimulated (Fonseca et al., 1995; 
Stanasila et al., 2008; Castillo-Badillo et al., 2015); this internalization leads to 
desensitization and down regulation of the receptors. Eventually, the receptors are 
recycled back to the plasma membrane or degraded by the lysosome (Castillo-Badillo 
et al., 2015). These mechanisms may explain phenylephrine-induced 1-AR mRNA 
downregulation in primary keratinocytes. Unfortunately, due to the limited supply of 
primary keratinocytes, these changes could not be confirmed at the protein level. 
Nevertheless, the mRNA reduction did not hinder the effect of 1-AR signalling on 
inflammatory mediator levels. These results may indicate that the induction of IL-6 
levels through 1-AR signalling was rapid, possibly preceding 1-AR downregulation.   
In summary, our findings indicate that keratinocytes may play an important role in 
local inflammatory responses and the development of persistent inflammation in 
CRPS. This may be mediated through a positive feedback interaction between 1-AR 
and inflammatory mediators, in particular IL-6 and NGF. We acknowledge that the 
small number of participants (CRPS patients and healthy volunteers) was a limitation 
of this study. Nevertheless, a vicious cycle between 1-AR and IL-6 in CRPS 
keratinocytes, particularly those with high baseline levels of 1-AR expression, was 
identified. Thus, targeting the interaction between 1-AR and inflammatory mediators 
may be a useful therapeutic strategy to hinder the development of persistent 
inflammation and pain in CRPS patients and, ultimately, to prevent the progression 
of CRPS into a chronic stage.  
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Chapter 6. General Discussion 
6.1. Results summary  
In this study, the role of alpha1-adrenoceptors (1-AR) in cutaneous inflammation was 
investigated utilizing in vitro, in vivo and ex vivo approaches. In Chapter 2, it was 
shown that in vitro administration of the pro-inflammatory mediator tumour necrosis 
factor  (TNF) induced an inflammatory state in an immortalized human keratinocyte 
cell line (HaCaT cells), characterised by increased levels of the pro-inflammatory 
cytokines interleukin (IL)-1, IL-6, IL-8, and nerve growth factor (NGF). Moreover, 
TNF or the inflammatory state induced by TNF, heightened the expression of 1-
AR subtype B (1B-AR) in these cells. In Chapter 3, the consequences of this 
heightened 1-AR expression were further investigated. The 1-AR agonist 
phenylephrine was administered to activated HaCaT cells following TNF treatment, 
with the results showing that stimulation of 1-AR on activated HaCaT cells further 
increased production of IL-6 from these cells compared to HaCaT cells that were 
treated with TNF only. These results suggested a positive feedback interaction 
between 1-AR and TNF in promoting pro-inflammatory IL-6 production in 
keratinocytes.  
In Chapter 4, an in vivo model of cutaneous inflammation was used to further 
investigate the role of 1-AR in skin inflammation and to confirm the observations 
seen in vitro. UVB irradiation was applied to the skin of healthy people to induce 
inflammation, as evidenced by histological changes in the skin, including a thickened 
epidermal layer, the presence of necrotic cells in the epidermis, dysplasia of the 
epidermis, and an increase in cellular infiltrates in the dermis although, unexpectedly, 
there were no changes in inflammatory cytokine production. However, a perfusion of 
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phenylephrine through microdialysis fibres induced greater IL-6 production in UVB-
exposed skin compared to saline perfusion in UVB-exposed skin, again suggesting a 
synergy between keratinocyte activation and 1-AR signalling in promoting pro-
inflammatory IL-6 production. 
In the final experiments (Chapter 5), the interaction between inflammatory mediators 
and 1-AR was investigated in primary keratinocytes obtained from patients with 
complex regional pain syndrome (CRPS), as an ex vivo pathological model. One of 
the clinical presentations seen in CRPS is persistent cutaneous inflammation. Similar 
to the results seen in HaCaT cells, administration of TNF to primary keratinocytes, 
obtained both from healthy control volunteers and CRPS patients, resulted in an 
increase in inflammatory cytokines IL-1, IL-6, IL-8, whereas NGF levels were 
decreased. Following TNF treatment, phenylephrine administration to these cells 
further increased IL-6 and further decreased NGF levels. Due to a small number of 
participants, no differences were observed in inflammatory mediator levels produced 
by control and CRPS keratinocytes as a response to both TNF and phenylephrine 
treatments. Interestingly, 1-AR baseline protein levels in CRPS keratinocytes were 
positively correlated with IL-6 production from these cells in response to 1-AR 
stimulation. This suggests that CRPS keratinocytes with high baseline 1-AR protein 
expression responded strongly to 1-AR stimulation and resulted in a higher 
production of IL-6. 
In summary, throughout all the chapters, a positive feedback interaction between 1-
AR and IL-6 was demonstrated in vitro, in vivo and ex vivo, suggesting an important 
role of this interaction in cutaneous inflammation. 
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6.2. Mechanisms behind cross-talk between 1-AR and inflammatory 
mediators  
The mechanisms behind cross-talk between 1-AR and inflammatory mediators in 
keratinocytes are not totally understood. However, utilizing mouse cardiomyocytes 
and 1A-AR-over-expressed rat fibroblasts as models, Perez and colleagues 
investigated the mechanisms behind cross-talk between 1-AR and IL-6 in these cells. 
They showed that 1-AR stimulation stabilized IL-6 mRNA and maintained IL-6 
transcription factor, involving the p38 MAPK and NF-B inflammatory signalling 
pathways, which resulted in a higher production of IL-6 (Perez et al., 2009). In this 
study, a positive feedback interaction between 1-AR and IL-6 was demonstrated in 
keratinocytes. It is postulated that TNF induced IL-6 production from keratinocytes 
through activation of canonical inflammatory signalling pathways, such as NF-B, 
JAK-STAT, and MAPK (Tanabe et al., 2010). Subsequently, stimulation of 1-AR 
following TNF treatment stabilized the production of IL-6 mRNA previously induced 
through TNF signalling pathways and maintained transcription factors for IL-6 
activated through TNF-induced NF-B and MAPK pathways (Perez et al., 2009).  
In murine splenocytes (leukocytes harvested from spleen), stimulation of 1-AR 
resulted in an increased production of IL-2 from these cells, accompanied by elevated 
phosphorylation of ERKs (extracellular signal-regulated kinases) and CREB (cAMP 
response element-binding protein), a protein kinase involved in the MAPK/ERK 
pathway and a cellular transcription factor, respectively (Priyanka & ThyagaRajan, 
2013). A recent study by Tripathi and colleagues suggested that cross-talk between 
1-AR and inflammatory mediators was mediated through a direct interaction 
between 1-AR and inflammatory mediator receptors (Tripathi et al., 2015). They 
found a heteromerization of 1-AR and chemokine receptor motif 4 (CXCR4) in 
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vascular smooth muscle cells. Thus, the binding of chemokine ligands to CXCR4 also 
modulates 1-AR physiological function in these cells, and vice versa. 
The mechanisms behind cross-talk between 1-AR and inflammatory mediators in 
keratinocytes requires further investigation. Measurement of proteins involved in (1) 
downstream 1-AR signalling pathway activation, such as phospholipase-C (PLC) 
(Xiao et al., 2010), (2) transcription and translation regulation pathways, such as in 
MAPK/ERK and JAK/STAT pathways, and (3) inflammatory signalling pathways, 
such as in the NF-B pathway, will give insights into the mechanisms involved in 
cross-talk between 1-AR and inflammatory mediator production in keratinocytes.   
 
6.3. Possible implications behind 1-AR and inflammatory mediator 
interactions  
Modulation of inflammatory mediator production from cells or tissues via 1-AR activation 
has been demonstrated in several studies (Grisanti et al., 2011b; Huan et al., 2017; Rossi 
et al., 2018). While this may be a normal physiological process, dysregulation of this 
interaction may compromise normal inflammatory processes and normal physiological 
functions of the cells and tissues. 
Activation of immune cells, such as peripheral blood mononuclear cells (PBMCs) and 
monocytes, increases 1-AR expression to detectable levels compared to the expression 
in resting cells (Heijnen et al., 1996; Rouppe van der Voort et al., 1999, 2000). Stimulation 
of 1-AR in these activated cells further induces inflammatory cytokine production 
(Grisanti et al., 2011b). Subsequently, these inflammatory cytokines enhance 1-AR 
expression in these cells (Heijnen et al., 2002), thus establishing a positive feedback loop 
between 1-AR and inflammatory cytokines. Maintaining homeostasis of this vicious cycle 
is important because, if unchecked, this interaction may enhance inflammatory responses 
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and result in the development of a chronic inflammatory condition such as juvenile 
rheumatoid arthritis (Heijnen et al., 1996; Roupe van der Voort et al., 2000). 
In a rat model of endotoxemia (acute sepsis), an increase in cytokines released as a 
response to an intravenous injection of bacterial lipopolysaccharide (LPS), was 
associated with a decrease in 1-AR expression in peripheral tissues, such as heart, lung, 
kidney, and liver (Bucher et al., 2003). This 1-AR downregulation explains the 
unresponsiveness of these patients to noradrenaline treatment to treat sepsis-induced 
hypotension, which leads to the development of heart failure. However, targeting an 1-
AR and inflammatory cytokines interaction via inhibition of the NF-B inflammatory 
signalling pathway attenuated cytokine production and prevented 1-AR downregulation 
in this model (Schmidt et al., 2009). In contrast, in the current study TNF (or an 
inflammatory state induced by TNF) caused an upregulation of 1-AR in keratinocytes. 
This discrepancy may be explained by the complexity of innate inflammatory signalling 
pathways activated by LPS through its receptors, toll-like receptors (TLRs) on multiple 
cell types (Biron, 2016). Activation of TLRs by LPS in sepsis results in over production of 
a range of inflammatory cytokines to create a cytokine storm that may over-stimulate 1-
AR and subsequently lead to a compensatory downregulation of 1-AR. 
 
6.4. The interaction between the sympathetic nervous system 
neurotransmitters, adrenoceptors and inflammatory mediators: 
implications in chronic pain conditions and chronic skin 
inflammatory diseases  
Inflammation is an important physiological process in our body. However, in some 
pathological conditions, such as chronic pain or chronic inflammatory skin diseases, 
excessive inflammatory responses, influenced by sympathetic dysfunction, may 
contribute to the progression of these conditions into a chronic stage.  
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Neuropathic pain is a type of chronic pain that arises from an injury or disease 
affecting the somatosensory system. Growing evidence from our laboratory and 
others has shown that 1-AR expression is increased in the skin of the symptomatic 
limb of CRPS patients (Finch et al., 2014; Drummond et al., 2018) and in skin of 
neuropathic pain animal models (Drummond et al., 2014a; Drummond et al., 2014c). 
In addition, elevated pro-inflammatory cytokine levels are also observed in the skin 
or blister fluid obtained from the affected limb of patients suffering from CRPS 
(Huygen et al., 2002; Groeneweg et al., 2006; Heijmans-Antonissen et al., 2006; 
Kramer et al., 2011; Birklein et al., 2014). The results of the current project suggest 
that inflammatory mediators released from keratinocytes as a response to an injury 
induce 1-AR expression (Chapter 2; (Wijaya et al., 2020b)). Subsequently, 
catecholamines released through activation of the sympathetic nervous system may 
further stimulate this heightened 1-AR expression and result in an increased 
production of inflammatory mediators (Chapter 3; (Wijaya et al., 2020a)). This vicious 
cycle between 1-AR and inflammatory mediators appears to be dysfunctional in 
neuropathic pain and may promote a persistent inflammatory state in the affected 
limb. In addition, inflammatory mediators can induce pain by acting on their receptors 
on the primary afferent sensory neurons that innervate the epidermis (Chao, 2003; Ji 
et al., 2014; Cook et al., 2018). Thus, excessive production of inflammatory mediators, 
as a result of dysregulation of 1-AR, may contribute to the development of persistent 
pain. While persistent inflammation is present in the acute stage of CRPS and 
attenuates as the condition progresses to the chronic stage, this study has shown 
that keratinocytes isolated from patients with chronic CRPS were sensitive to 1-AR 
stimulation, and this triggered an increase in production of IL-6 in proportion to basal 
1-AR protein levels. Hence, catecholamines released during stressful events may 
re-activate the vicious cycle, particularly in a subset of CRPS patients with evidence 
of sympathetically maintained pain. 
Chapter 6. General Discussion 
 111 
In chronic inflammatory skin diseases, such as psoriasis and atopic dermatitis, levels 
of noradrenaline are increased in the affected skin (Hall et al., 2012). The aetiology 
and pathophysiology of these skin diseases are not totally understood; however, 
psychological stress is known to aggravate these conditions. Basal catecholamine 
(Buske-Kirschbaum et al., 2002a) and immunoglobulin E (IgE) levels (Buske-
Kirschbaum et al., 2002b) were elevated in atopic dermatitis patients compared to 
that in healthy controls and interestingly, both catecholamines and IgE levels were 
significantly elevated after administration of a standardized psychosocial stressor. In 
addition, an increased number of mast cells is observed in affected skin compared to 
unaffected skin (Lonne-Rahm et al., 2008). Moroni and colleagues showed that 1-
AR mediated noradrenaline-induced histamine release from murine neoplastic skin 
mast cells (Moroni et al., 1977)  and this could further induce inflammatory responses 
from other resident skin cells (Navi et al., 2007). Together, this may imply that in 
atopic dermatitis, enhanced catecholamine release during stressful events may 
enhance cutaneous inflammatory responses, mediated by 1-AR.  
 
6.5. The role of keratinocytes in mediating cross-talk between the 
sympathetic nervous system and immune system  
Keratinocytes, the most abundant cells in the epidermis, provide a barrier against 
environmental hazards and produce inflammatory mediators. An injury triggers pro-
inflammatory cytokine production, such as TNF, IL-1, and IL-6, from keratinocytes 
and these cytokines act as signals to recruit other immune cells from the circulation. 
Moreover, activated Langerhans cells (a type of dendritic cell, which resides in the 
basal layer of the epidermis) and resident macrophages also release inflammatory 
cytokines to enhance the attractant signals to recruit peripheral immune cells to the 
injury site. Both Langerhans cells and macrophages are considered messengers 
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between the innate and adaptive immune system. Inflammatory cytokines also induce 
the expression of 1-AR in keratinocytes (Chapter 2; (Wijaya et al., 2020b)) and 
immune cells (Heijnen et al., 2002), which increases the responsiveness of these 
cells to adrenergic stimulation.  
Sympathetic nerve endings innervate the epidermal layer of the skin and are in close 
contact with keratinocytes (Albers et al., 1994). Following injury, catecholamines 
released from sympathetic nerve endings stimulate adrenoceptors expressed in skin 
cells and resident immune cells to further release inflammatory cytokines and initiate 
wound healing processes (Heijnen et al., 1996; Sang et al., 2007; Grisanti et al., 
2011b; Wallert et al., 2011; Lei et al., 2013; Drummond et al., 2014b; Drummond et 
al., 2014a; Drummond et al., 2014c; Drummond et al., 2015; Wijaya et al., 2020a). 
Physiological levels of noradrenaline play an important role in wound healing. In 
normal rats, noradrenaline released after injury enhances the recruitment of 
neutrophils and macrophages to the injury site, reduces wound angiogenesis and 
induces keratinocyte migration to augment wound re-epithelization (Gosain et al., 
2006). However, excessive stimulation of adrenoceptors may lead to impaired wound 
healing (Lei et al., 2013; Sivamani et al., 2014). Together, this evidence highlights the 
importance of keratinocytes as a mediator for cross-talk between the SNS and 
immune cells in the skin.  
 
6.6. Limitations of this study  
This study has demonstrated a positive feedback interaction between 1-AR and the 
inflammatory cytokine IL-6 in vitro, ex vivo and in vivo. However, it is acknowledged 
that there were some experimental limitations. First, an immortalized keratinocyte cell 
line (HaCaT) was used as an in vitro model to simplify the investigation into the role 
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of 1-AR in cutaneous inflammation. However, since skin is a complex organ, the 
interaction between 1-AR and inflammatory mediators in vivo might be slightly 
different and involve interaction with other resident cells, such as fibroblasts, 
macrophages, and sensory neurons. This includes the interaction with 1-AR 
expressed on those cells and inflammatory mediators produced by these cells. Thus, 
further studies investigating this interaction in other resident skin cells and utilizing a 
co-culture system to investigate the interaction between the cell types will be 
beneficial to provide better insights into the interaction between 1-AR and 
inflammatory mediators in the skin.   
Second, while human primary keratinocytes obtained from skin biopsies most likely 
model in vivo processes more closely than HaCaT cells, their short lifespan in culture 
was one of the limitations in this study. Indeed, primary keratinocytes were less 
proliferative and less responsive to exogenous TNF than HaCaT cells. This might 
have resulted in a reduction of inflammatory cytokines and NGF production from 
primary keratinocytes, compared to HaCaT cells. 
Third, in the microdialysis experiment it was found that cutaneous inflammation 
induced by UVB exposure to the skin varied among individuals, possibly due to 
differing skin types. In addition, we found that the skin response to 1-AR stimulation 
post-UVB irradiation resulted in inconsistent IL-6 production. Therefore, further 
studies involving additional participants and a stronger model of cutaneous 
inflammation (Holzmann et al., 2004) could provide a clearer insight into the role of 
1-AR in cutaneous inflammation and its interaction with inflammatory mediators, in 
vivo. 
Lastly, the recruitment of CRPS patients was difficult due to the low incidence of 
CRPS (Sandroni et al., 2003; de Mos et al., 2007) and because of time constraints in 
this study, only a small number of participants (both CRPS patients and healthy 
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volunteers) could be recruited for the primary keratinocyte experiments. Moreover, 
we found that there were great differences in individual baseline 1-AR expression 
levels, which may result in high variability of primary keratinocyte responses to 1-AR 
stimulation. In addition, the complex diversity of CRPS phenotypes, which may 
involve different pathophysiological mechanisms, may also contribute to these 
individual differences. Together, this may explain why there were no significant 
differences in inflammatory cytokine and NGF production between CRPS and healthy 
control keratinocytes post-1-AR stimulation. Therefore, including more participants 
would enrich our current results. In addition, a higher number of CRPS patients would 
allow us to categorize them into different CRPS subtypes (type I, type II, acute stage, 
chronic stage, warm and cold CRPS, etc) and investigate whether the interaction 
between 1-AR and inflammatory mediators differed between the subtypes.  
 
6.7. Future directions 
At the beginning of the study, an in vitro scratch assay was utilized to apply a 
mechanical injury to keratinocytes and subsequently induce inflammatory mediator 
production from these cells. Following thorough assessment, the scratch assay was 
found not to be a suitable technique to induce an inflammatory state in these cells 
(see Appendix A). Thus, administration of TNF to keratinocytes was used as an 
alternative approach to induce an inflammatory state. As demonstrated in this study, 
TNF increased inflammatory mediator production and 1-AR expression in 
keratinocytes. In turn, stimulation of this heightened 1-AR expression further induced 
IL-6 production from keratinocytes. Although the scratch was not successful in 
inducing inflammation, it is important to explore other approaches (e.g., mechanical 
trauma; exposure to ultra-violet radiation; or low pH), as this might more closely mimic 
inflammation in vivo. 
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Future studies can be proposed to provide more insights into the role of 1-AR in 
cutaneous inflammation and its positive feedback interaction with inflammatory 
mediators in the skin. An important next step would be to clarify the involvement of 
several signalling pathways, such as MAPK/ERK, NF-B, JAK-STAT, underlying this 
positive feedback interaction in keratinocytes.  
Since this study showed that IL-6 production was heightened by synergism between 
1-AR and inflammatory mediators in the skin, future studies investigating the 
consequences of this heightened IL-6 expression in the skin will be needed. 
Specifically, over-production of IL-6 has been associated with autoimmune and 
chronic inflammatory disease, such as rheumatoid arthritis and systemic lupus 
erythematosus (Hirano, 2010). This might also be important in CRPS, as an 
autoimmune component may contribute to CRPS (Goebel & Blaes, 2013). Moreover, 
further studies involving co-culturing techniques using keratinocytes and other types 
of skin cells, such as fibroblasts, sensory neurons and macrophages, could be utilized 
to further investigate the role of 1-AR in cutaneous inflammation and how this cell-
to-cell interaction affects synergism between 1-AR and inflammatory mediators.   
 
6.8. Conclusions  
The results from these studies confirm that inflammatory mediators such as TNF 
can induce 1-AR expression on keratinocytes in the skin that, together with 
catecholamines released by sympathetic nerves following skin injury, could act 
synergistically to activate keratinocytes via elevated 1-AR expression levels. As a 
result, heightened signalling through 1-AR may synergistically induce over-
production of IL-6 from resident keratinocytes, thus acting to promote an inflammatory 
cascade. Although this interaction may be a normal cutaneous inflammatory process, 
Chapter 6. General Discussion 
 116 
restoring the homeostasis levels of 1-AR following injury could be crucial to prevent 
the development of persistent inflammation. Furthermore, targeting this interaction 
may be a useful therapeutic target to hinder the development of persistent 
inflammation and pain, such as in CRPS, and, ultimately, to prevent the progression 
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Appendix A. Assessment of in vitro scratch assay to 
induce inflammation in keratinocytes 
A.1. Introduction 
Epidermal keratinocytes and other resident skin cells produce inflammatory 
mediators, such as tumour necrosis factor alpha (TNF), interleukin (IL)-1, IL-8 and 
IL-6, to promote acute inflammatory responses and initiate the healing process after 
injury (Zhang & An, 2007). Moreover, keratinocytes express 1-AR (Dawson et al., 
2011; Li et al., 2013; Finch et al., 2014) and the expression is heightened in the skin 
isolated from the affected limb of patients with chronic pain conditions, such as 
complex regional pain syndrome (CRPS; (Birklein et al., 2014; Drummond et al., 
2014b; Drummond et al., 2014a; Drummond et al., 2014c; Finch et al., 2014; 
Drummond et al., 2018). However, the role of 1-AR in cutaneous inflammation and 
a potential interaction between 1-AR and inflammatory processes in the skin are not 
well understood.  
The aim of this study was to investigate whether inflammatory mediators released 
from keratinocytes can trigger 1-AR expression in these cells. This is the first step to 
elucidate if the interaction between inflammatory mediators and 1-AR is present in 
keratinocytes. The in vitro scratch assay (Liang et al., 2007) was utilized to apply a 
mechanical injury to an immortalized human keratinocyte cell line (HaCaT cells; 
(Boukamp et al., 1988)). It was hypothesized that the scratch assay would induce 
inflammatory cytokine production from HaCaT cells and that this scratch-induced 
inflammatory state would then heighten 1-AR expression in HaCaT cells.  
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A.2. Material and Methods 
A.2.1. Cell maintenance 
The materials used for maintenance of the cells were purchased from GibcoTM 
(Thermo Fisher Scientific, MA, USA), unless otherwise stated. The immortalized 
human keratinocyte cell line (HaCaT cells) was obtained from the German Cancer 
Research Centre (DKFZ, Heidelberg, Germany; Cat No. 300493) (Boukamp et al., 
1988). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM), 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Serana, Bunbury, 
Australia) and maintained in a controlled incubator at 37oC with 5% CO2.  
 
A.2.2. In vitro scratch assay 
The in vitro scratch assay was performed according to Liang et al. (Liang et al., 2007) 
with some slight modifications. Briefly, three straight lines were drawn underneath 
each well of a 6-well cell culture plate using an ultrafine tip marker and used as a 
guide for placing the scratches. The first line was drawn in the middle of the well and 
the other two lines were 5 mm away to the left and to the right from the middle line. 
For the experiment, HaCaT cells were plated in marked cell culture plates at 150,000 
cells/well for 2 days prior to applying the scratches. Three scratches per well were 
applied on the guide lines using 200 l pipette tips. A glass slide was used as a 
straight edge while making the scratches. Three-vigorous PBS washes were applied 
to remove the remaining cell debris around the scratch/wound area. To determine the 
optimal time to induce inflammatory cytokine production from HaCaT cells, the cells 
were further incubated in reduced serum media (0.2% FBS) for 6, 12, 24, 33 or 48 h. 
At the end of each time point, an image of HaCaT cells was taken at the middle 
scratch under a phase-contrast light microscope (Olympus CK40 inverted microscope) 
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at 4x magnification. The cells were then washed once with PBS and lysed with lysis 
buffer for total RNA isolation. Each set of experiments was repeated three times. 
 
A.2.3. Quantitative real-time PCR 
Total RNA was isolated and purified from the cell lysates using an Aurum total RNA 
mini kit (Bio-Rad Laboratories, CA, USA). One g total RNA was converted to cDNA 
using an iScript™ Reverse Transcription Supermix (Bio-Rad Laboratories, CA, USA), 
with the following cycle: 5 min priming step at 25oC, followed by a reverse transcription 
step at 42oC for 30 min and reverse transcriptase inactivation at 95oC for 5 min. A 
SYBR® Green-based quantitative real-time PCR (qRT-PCR) assay, followed by 
melting curve analysis, was used to measure gene expression levels of 1-AR 
subtype B (1B-AR) and inflammatory cytokines IL-1, IL-6 and IL-8. Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) was used as an endogenous control. The 
primer sets used in qRT-PCR are listed in Table A-1. All of the primers were validated 
to amplify mRNA-derived transcripts but not genomic DNA (unpublished data). The 
qRT-PCR assay was performed using a ViiA™ 7 Real-Time PCR System (Applied 
BiosystemsTM; Thermo Fisher Scientific, MA, USA). A cycle threshold (Ct) value of 
each sample was collected at the end of the qRT-PCR run (40 cycles). Changes in 
gene expression as a result of the treatments compared to the naïve (non-scratch) 
group at each time point were represented in Ct, where Ct=(Ctnaïve–Ctscratch), 
Ctnaïve=(Ctnaïve–CtGAPDH), and Ctscratch=(Ctscratch–CtGAPDH) (Yuan et al., 2006; 
Schmittgen & Livak, 2008). The mean  SEM of the gene expression changes 
between biological replicates is presented in the Results section. 
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Table A-1. Primer sets used in a SYBR® Green qRT-PCR assay  
 
 
A.2.4. Statistical analysis 
At each time point, the Ct mean values of naïve [Ctnaïve=(Ctnaïve–CtGAPDH)] and 
scratch [Ctscratch=(Ctscratch–CtGAPDH)] cells were analysed using a paired sample t-test 
to determine the mean difference between treatments. All statistical analysis was 












‘5 – 3’ 
Reverse Sequence 





NM_000584 ATG ACT TCC AAG CTG GCC GT TCC TTG GCA AAA CTG CAC CT 82 
IL6 
(IL-6) 
NM_000600 AGC CCT GAG AAA GGA GAC ATG ACC AGG CAA GTC TCC TCA TTG 144 
IL1B 
(IL-1) 
NM_000576 CTG TCC TGC GTG TTG AAA GA TTG GGT AAT TTT TGG GAT CTA CA 70 
NGF 
(NGF) 
NM_002506 TGT GAT CAG AGT GTA GAA CAA CA CGG ACC CAA TAA CAG TTT TAC C 97 
GAPDH NM_002046 GGG TGT GAA CCA TGA GAA GAC TGT GGT CAT GAG TCC T 136 
ADRA1B 
(1B-AR) 
NM_000679 PrimePCR SYBR Green Assay (assay ID: qHsaCIP0030605). 112 
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A.3. Results 
Following the scratch assay, images of HaCaT cells were acquired under a phase-
contrast microscopy at the end of each time point to observe the wound closure. As 
seen in Figure A-1, HaCaT cell migration to the wound area was observed over time 
and the wound was nearly closed at 48 h post-scratch. However, the scratch 
application did not alter inflammatory cytokine (Figure A-2 A-C) or 1B-AR (Figure A-
2 D) gene expression levels in HaCaT cells at any time point, except a reduction in 
IL-6 gene expression levels in the scratch condition compared to naïve cells at 24 h 
post-scratch. Moreover, both inflammatory cytokine and 1B-AR gene expression 
levels varied highly among the biological replicates.    
 
Figure A-1. HaCaT cells migration following in vitro scratch assay  
The scratch assay was applied to HaCaT cells using 200 l pipette tips. The 
representative images were acquired at 0 (non-scratch/naïve), 6, 12, 24, 33 and 48 h 
(hours) post-scratch with a phase-contrast light microscope at 4x magnification.   
 




Figure A-2. Inflammatory mediator and 1B-AR gene expression levels post-
scratch in HaCaT cells 
The scratch assay was applied to HaCaT cells using 200 l pipette tips. Following the 
scratch assay, the cells were further incubated in reduced serum media for 6, 12, 24, 
33, and 48 h (hours). Naïve cells (non-scratch cells) treated with reduced-serum 
media only were used to estimate baseline expression level at each time point. Gene 
expression levels of inflammatory cytokines: (A) IL-1, (B) IL-8, (C) IL-6, and (D) 1B-
AR were measured at each time point. Changes in gene expression as a result of the 
scratch assay compared to the naïve condition are represented as Ct (CtNaïve=0). 
Data are represented as mean  SEM of three independent replicates; *p<0.05 
compared to naïve at the same time point. 
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A.4. Discussion 
The effects of the scratch assay on inflammatory mediator production in HaCaT cells 
were investigated in vitro. The scratch assay was utilized to mimic a mechanical injury 
to cultured HaCaT cells. Keratinocyte migration and wound closure were observed 
over time and this wound closure was almost completed at 48 h post-scratch. An 
inflammatory state was not induced by the scratches, marked by no changes in 
inflammatory cytokine gene expression levels in HaCaT cells. Furthermore, the 
scratch assay did not alter 1B-AR gene expression levels. 
The in vitro scratch assay has been widely utilized in wound healing and cell migration 
studies (Walter et al., 2010; Sivamani et al., 2014). However, utilization of this 
technique to induce inflammation in vitro has not been reported. The results from this 
study demonstrated that applying the scratch assay to cultured keratinocytes did not 
induce inflammatory cytokine production in these cells, although it induced 
keratinocyte proliferation and migration that supports the wound closure. This may be 
because the scratch only scraped the cells from the growth surface without inducing 
any inflammatory processes in the keratinocytes. In addition, in vivo, the inflammatory 
cytokines released from keratinocytes following an injury may be induced by pro-
inflammatory mediators released by local inflammatory cells that are involved in acute 
inflammatory responses, such as neutrophils and macrophages (Yeh et al., 2017).  
The reduction of IL-6 gene expression levels observed in the scratch condition at 24 
h post-scratch was unexpected and the mechanism behind this scratch-reduced IL-6 
levels needs to be explored further. However, as the decrease in IL6 was significant 
at only one time point, 24 h after the scratch, it may have been a chance effect. 
In conclusion, while the in vitro scratch assay is useful in wound healing and cell 
migration studies, this technique was not suitable as a technique to induce an 
inflammatory state in cultured keratinocytes. Administration of pro-inflammatory 
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cytokines that are present at the inflammatory phase following an injury, such as 
TNF (Robson et al., 2001), may be a better approach to induce inflammatory 
conditions in cultured keratinocytes and to investigate the effects of inflammatory 
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